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Abstract

Research Involving Children: Regulations, Review Boards and Reform. Rupali Gandhi
(Sponsored by Dr. Robert J. Levine). Department of Internal Medicine, Yale University, School of
Medicine, New Haven, CT.

Children have been the victims of unethical clinical investigations since the earliest
clinical research trials. Although children are vulnerable and require additional protections
when participating in research, they should not be disallowed from research altogether because
this is more detrimental to their well being than permitting their participation. The ethical
principles of respect for persons, beneficence and justice serve as the foundation for the federal
regulations, adopted in 1981, which serve to protect human subjects in research. Although the
regulations were a vast improvement over prior codes, they continue to use an array of vague
language that leaves substantial room for debate in their interpretation. Several hypothetical
cases and two recent controversial cases exemplify how reasonable people continue to disagree
over how the regulations should be interpreted and applied. One problem with the current
review system is its almost total reliance on the efficiency and knowledge of local institutional
review boards. The creation of a hierarchical review board system that maintains the local
institutional review boards (IRBs) but creates many regional boards and one national board
analogous to the federal court structure will have a positive impact on the current regulatory
system. The establishment of a more centralized system that still maintains a degree of flexibility
will encourage greater consistency between interpreters of the regulations, provide an appeals
process for individual investigators, and create one national board with the requisite case
experience and knowledge of how the regional and local review boards operate to enable it to
promulgate memoranda that clarify the interpretation of the federal regulations as needed.
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Introduction
Historical Perspectives: Past to Present
Children have been the victims of unethical clinical investigations since the earliest
clinical research trials.1 In 1789, Edward Jenner, an English researcher trying to discover a
vaccination for smallpox, initially injected his own one-year-old son with cowpox to determine
whether it would offer protection against smallpox. Next, he gave an eight-year-old child a
challenge of smallpox material to see if a prior vaccination would be effective. Later, in 1802, a
physician for an almshouse gave the vaccine to 48 children who were under his care and later
challenged the vaccine by inoculating the children with smallpox material.2 3 Although these
initial vaccination trials posed obvious danger to the children who were inoculated, the trials
were justified by arguing that the possible benefits to children as a group outweighed the risks
inflicted on the few children who were the initial subjects.
Although research on children continued, there were at least some physicians who
objected to the use of children in medical experiments in which subjects were purposely injured
in order to obtain scientific evidence for a disease course. In 1941, the editor of the Journal of
Experimental Medicine, Francis Payton Rous, wrote in his rejection of a manuscript that "the
inoculation of a twelve month old infant with herpes... was an abuse of power, an infringement
of the rights of an individual, and not excusable because the illness which followed had
implications for science."1 His opinion, however, had little impact on the academic community
and the research results were published in the Journal of Pediatrics.4
From the 1950s through the 1970s a set of experiments were conducted at the
Willowbrook State School, a New York State institution for mentally disabled children. The

1 See Leanord H. Glantz , Research With Children, 24 AM. J.L. & MED. 213, 215 (1998). See also Susan
E. Lederer & Michael Grodin, Historical Ovennew: Pediatric Experimentation, in CHILDREN AS RESEARCH
Subjects: Science, Ethics and Law 3 (Michael A. Grodin & Leanard H. Glantz eds., 1994).
2 See Lederer & Grodin, supra note 1, at 5.
3 See id. at 14.
4 See id.

-
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research was intended to help elucidate the natural course of hepatitis." Researchers
systematically infected mentally disabled children with a hepatitis virus. Early subjects were
given extracts of stool from infected persons, and later subjects were injected with purified virus
preparations.5 6 7 8 9 The researchers justified their actions by claiming that 85% of the children in the
institution would contract the disease in the first year of admission anyway, and systematic
infection would allow the investigators to study the natural course of the disease. The institution
was closed to new children because of its overcrowded conditions, but the hepatitis program,
with its own space in the building, was able to admit new members. Therefore, in order to have a
child accepted to Willowbrook, parents often had to accept their child's participation in the
hepatitis program.' When the Willowbrook experiments were brought to public attention in the
1970s there was a huge outcry.*

It was unimaginable that innocent children had intentionally

been given a serious illness and their parents, desperate to find care for their disabled children,
had been coerced into permitting their participation. Furthermore, the researchers' justification
that the children would have likely contracted hepatitis anyway only emphasized the terrible
unsanitary conditions in which these mentally disabled children were housed. Finally, the legal
authority of parents to volunteer their children for this research was questioned.^
As these examples reflect, children have not been adequately protected from unethical
clinical research. It is not enough to believe that researchers will conduct their work with
adequate protection for children on their own accord. Eliot Friedson writes that the professional

5 See id. at 17. See also Robert J. Levine, Ethics and Regulation of Clinical Research, 70 (Yale
Univ. Press 2d ed. 1988) (1986).
6 See Levine supra note 5, at 70.
7 See id.
8 Some results from the Willowbrook studies had been published in the New England Journal of Medicine
in 1958 with few if any objections, but after the public took notice in the 1970s, “a furor attends the
appearance of any Willowbrook report, even though the report may present no more than the results of
continued surveillance of children infected at an earlier date.” F.J. Ingelfmger, Ethics of Experiments on
Children, 288 New ENGLAND J. MED. No. 15, 791.
9 See, e.g., Glantz, supra note 1 at 217. But see id. at 792. Ingelfmger writes that even after the public
outcry some researchers believed that the risks imposed on the children were permissible given the risks of
being a patient in the unsanitary conditions of Willowbrook. He states that perhaps “some broadly based
system can be set up to determine under what conditions children or mentally incompetent persons can be
used for experimentation not primarily designed for their benefit. This is the only reasonable way; it is also
the only honest way.”

3

privilege of self-regulation has been justified on several grounds including that the profession
"may be trusted to undertake the proper regulatory action on those rare occasions when an
individual does not perform his work competently or ethically."10 He is skeptical, however, that
self-regulation works in medicine because the ability to observe performance is a prerequisite for
regulation, and he doubts that the structure of the medical profession has an appropriate level of
observability.11 Furthermore, he asserts that medical norms seem to discourage self-regulation.12
Talcott Parsons, by contrast, argues that professions are limited from perfect efficiency due to
social constraints.1' The profession's ability to function appropriately depends on an institutional
structure "the maintenance of which...involves a complex balance of diverse social forces."14
Certainly, institutional review boards (IRBs) are a form of self-regulation by the medical
community to ensure that investigators engaged in research protect the rights and welfare of
human subjects. Although many would assert that they do an admirable job, several IRBs have
been accused of not protecting human subjects adequately.1' Perhaps, however, it is not that self¬
regulation is impossible or undesirable, but rather the institutional structure of the regulatory
system that needs to be recalibrated.
Unfortunately, examples of unethical research involving children are not only in the
distant past. The truth remains that even with protections that were adopted into law in the early
1980s there remain incidents where children have been the subjects of research deemed unethical.
The existence of the current federal regulations does not guarantee that there will be compliance
with the spirit underlying the words of the regulations or complete agreement over what
constitutes ethically acceptable research. The current system relies heavily on IRBs to function
appropriately and interpret the federal regulations with careful deliberation. Case examples,

10 See Eliot Friedson, Profession of Medicine: A Study of the Sociology of Applied Knowledge,
137 (Univ. of Chicago Press 1988).
11 See id. at 157.
12 See id. at 184.
13 See Talcott Parsons, Essays in Sociological Theory, 35 (Free Press rev. ed. 1954) (1949).
14 Id. at 48.
15 One might argue, however, that inherent uncertainties in medical practice, knowledge and research
would lead to less-than-perfect outcomes even //IRBs functioned flawlessly. See Jay Katz, The Silent
World of Doctor and Patient 171 (Free Press 1984). See also Levine supra note5, at 127-128.
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however, demonstrate that reasonable people can and do disagree over how the regulations
should be interpreted and what types of research protocols are ethically permissible. Most
recently, a study of housing lead abatement conducted by affiliates of Johns Hopkins University
engendered differing opinions over what should be ethically acceptable.1'' Additionally, a
National Institute of Child Health and Human Development study using obese children and
children of obese parents was terminated for violating the federal regulations.1

This paper will

explain the special problems of involving children in research, provide a thorough understanding
of some of the past and current protections for human clinical research participants including the
current federal regulations, emphasize the more controversial areas, and make recommendations
on how the regulatory structure could be improved.
Part I will describe why children are unique in the research world. It will argue that
while children are vulnerable and require additional protections when participating in research,
they should not be disallowed from research altogether because this is more detrimental to their
well being than permitting their participation. Rather, children should be permitted to
participate in research but with additional safeguards in place that protect their vulnerable
situation.
Part II describes the historical context of human research protections including the
Nuremberg Code and the Declaration of Helsinki. It explores the ethical principles that have
been used to protect humans involved in clinical research and explains how these principles of
respect for persons, beneficence and justice are applied to persons with diminished capacity, such
as children. The unique characteristics of children make the application of these principles less
straightforward than when applied to research involving adults and their expression in
procedural and substantive norms is necessarily altered when applied to children.
The current federal regulations that govern human clinical trials involving children will
be scrutinized in Part III. The regulations were passed in the early 1980s, but were preceded by

16 See infra note 73 and accompanying text.
17 See infra note 91 and accompanying text.
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recommendations made by a national commission that was created several years earlier in the
aftermath of the Tuskegee syphilis experiments.

Although the regulations were a vast

improvement over prior codes, they continue to use an array of vague language that leaves
substantial room for debate in their interpretation. Several hypothetical cases and recent
controversial cases will be used to exemplify how reasonable people continue to disagree over
how the regulations should be interpreted and applied.
Finally, Part IV offers recommendations for change within the regulatory system. The
creation of a hierarchical review board system that maintains the local institutional review boards
but creates many regional boards and one national board analogous to the federal court structure
will have a positive impact on the current regulatory system. The establishment of a more
centralized system that still maintains a degree of flexibility will divide the duties between the
review boards according to their strengths, encourage greater consistency between interpreters of
the regulations, provide an appeals process for individual investigators, and create one national
board with the requisite case experience and knowledge of how the regional and local review
boards operate to enable it to promulgate memoranda that clarify the interpretation of the federal
regulations as needed.

Part I: Children in Research
Children are distinct from other human research subjects because they do not usually
have the maturity and knowledge base to make an informed decision. They are "incapacitated"
in the sense that one would not expect a five-year-old child to be able to comprehend, process,
engage in abstract reasoning or synthesize information in the same way as a twenty-five-year-old
person.

Children cannot be expected to make fully informed decisions regarding their own

participation in clinical trials that may or may not be of direct benefit to them. Surely, some
children will express opinions, but children can often be guided into making a decision based on
the viewpoint of a trusted adult or parent. In order to ensure that a child truly understands what

'
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is being asked of him and is not being coerced or improperly informed, special protections or
cautions must be used when children are research subjects.
Given the multiple examples where children have been mistreated in clinical research
trials, one might argue that children should not be permitted to participate in human
investigations at all. This approach, seemingly radical in the modern world, was indirectly
supported by the Nuremberg Code.1* Despite the desire to protect children from the possible
harms that can result from their participation in research, there are far more detrimental effects
that would result if children were prohibited from participation in human clinical investigations
altogether.
If research involving children (or any group having biological differences from the
"average" such as pregnant women) were disallowed, the medical progress for that population
would be halted as well. Diseases such as cystic fibrosis, phenylketonuria, Hirschprung's disease
and many congenital anomalies first manifest in childhood and if they are not treated early, the
child may not ever reach adulthood. In order to make advances in the treatment of these
diseases, a research study needs to enroll children who have the diseases in question. Without
such research, the children become "therapeutic orphans."1" They are left behind while medicine
advances for everyone else.
Furthermore, beyond research on childhood diseases, there is another category of
essential research - medication use in children - that lags far behind. Presently, most
medications used for children are used "off-label," meaning that they were never formally tested
on children; rather the adult doses are modified and then given to the child. Since 1962, the FDA
has required nearly all new drugs to be labeled with an "orphaning" clause such as "not
recommended for use in infants or children, since few studies have been carried out in this

18 Although the Nuremberg Code was silent with regard to children, it required legally capacity to give
consent for participation, and therefore, indirectly prevented children (who cannot legally consent) from
participation. See Appendix 2 for text of Nuremberg Code.
19 See Harry Shirkey, Editorial Comment: Therapeutic Orphans, 72 J. OF PEDIATRICS No. 1, 119 (1968).
See also Levine, supra note 5, at 239-241.
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group..."2'1 Nevertheless, the overwhelming majority of physicians ignore the orphaning clause
on the labels and use the medications for children anyway, albeit, usually at an adjusted dose.
The result of off-label usage is that it produces a greater risk to the child than if the child had been
part of a well-designed research protocol that tested different medication doses to determine the
appropriate level to be used. A child in a research study designed to test the best dose of a
medication would likely have more information about the medication, frequent surveillance of
side effects and a greater likelihood of having access to medical care should an adverse reaction
develop. Children given a medication off-label, however, do not have the same surveillance of
side effects and risk a greater possibility of harm if an adverse reaction occurs in an uncontrolled,
unmonitored setting. Robert Levine argues that the therapeutic orphan problem is a serious
injustice. He observes that "[i]f we consider the availability of drugs proved safe and effective
through the devices of modern clinical pharmacology and clinical trials a benefit, then it is unjust
to deprive classes of persons, e.g., children...of this benefit."21
The problem with the lack of clinical pharmacology studies in children is even more
concerning than the dearth of studies involving other vulnerable groups (such as prisoners or
mentally disabled individuals) because children often have smaller body sizes, different
physiology and different metabolisms (for example, the newborn liver does not metabolize
certain medications as efficiently as the adult liver), therefore improper medication doses for
children could lead to grave consequences more often than with adults. Logically then, it
appears that medications used in children should have more stringent testing than medications
used for adults. Yet the opposite is true: medications used for children have the least amount of
empirical evidence supporting their use.

20 See Shirkey, supra note 19, at 119.
21 See Levine, supra note 5, at 239. Levine states: “Parenthetically, it should be noted that most drugs
proved safe and effective in adults do not produce unexpected adverse reactions in children; however, when
they do, the numbers of harmed children tend to be much higher than they would be if the drugs had been
studied systematically before they were introduced into the practice of medicine.” Id. at 240-241.
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The Best Pharmaceuticals for Children Act of 2002“ gives financial incentives to
pharmaceutical companies that voluntarily decide to test their medications in children, but this
law clearly has not done enough considering that as of July 2003, three-fourths of all prescription
medications on the market had inadequate information regarding their safety in pediatric
populations.2' In 1998, the Food and Drug Administration (FDA) had attempted to alleviate the
problem by adopting a regulation known as the Pediatric Rule. The Rule required
pharmaceutical companies to test specific medicines in children before the drugs were marketed.
In October 2002, however, a judge ruled that the FDA did not have the authority to adopt the
Pediatric Rule and so it was struck down. Congress reacted, albeit slowly, and adopted the
Pediatric Research Equity Act of 2003 which was signed into law just recently in December 2003.
The law gives the FDA jurisdiction to require that drugs used in pediatric patients be
appropriately tested with pediatric populations prior to FDA approval. Recognizing the
importance of solving the therapeutic orphan problem, FDA Commissioner Mark McClellan
stated:
Prescription drugs can do more than ever to cure diseases,
including illnesses in children. But it is not good medicine to
assume that children can be treated like little adults. Parents and
health professionals deserve confidence that medicines used to
treat children are safe and effective. FDA will use this important
new law to require pediatric studies, when necessary, to give
parents and doctors the confidence they deserve.24

Undoubtedly, the Pediatric Research Equity Act is a step in the right direction towards
alleviating the therapeutic orphan problem and decreasing off-label medication use and its
associated risks. The law will lead to increased numbers of research trials involving children,
and although these studies should be conducted to benefit children, additional safeguards must

"2 Best Pharmaceuticals for Children Act, Pub. L. No. 107-109, (codifed as amended in scattered sections
of 21 U.S.C.) (text also available at: <http://www.fda.gOv/opacom/laws/pharmkids/pharmkids.html#secl>).
23 Participation and Protection of Children in Clinical Research, Before the Inst, of Med. Comm, on
Clinical Research Involving Children (July 9, 2003) (statement of David J. Schonfeld, member of the Am.
Acad, of Pediatrics Comm, on Pediatric Research) (text available at
<http://www.aap.org/advocacy/washing/David_Schonfeld_testimony.htm>).

■
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be in place to prevent their manipulation and exposure to unreasonable levels of possible harm.
The balance between encouraging research designed to help children as a group and preventing
unreasonably high levels of risk to any particular child in a study is difficult to strike. Ethical
principles can serve an important role by guiding decision-makers during difficult assessments.

Part II: Foundations of Research Ethics
From 1945-1947, the first international war-crimes trials were held in Nuremberg,
Germany in order to bring justice to the Nazis who committed terrible offenses during World
War II. Many of the crimes included horrific murders and tortures conducted in the name of
medical research. The three Nuremberg judges were infuriated by the atrocities committed using
science as a justification and decided to codify fundamental ethical guidelines for permissible
human research "in order to satisfy moral, ethical and legal concepts."1' The Nuremberg Military
Tribunal's decision in United States v. Karl Brandt et al. included a ten-point statement that
described permissible medical experiments on human subjects. These ten principles became
known as the Nuremberg Code, and the Code is generally regarded as the first international
document to set out ethical regulations in human experimentation based on informed consent.2h
(See Table 1.)

24 Press release on the signing of the Pediatric Research Equity Act of 2003 (Dec. 3, 2003) (statement of
Mark B. McClellan, Commissioner of the Food and Drug Administration) (text available at
<http://www.fda.gov/bbs/topics/NEWS/2003/NEW00989.html>).
25 Nuremberg Code. Reprinted in Levine, supra note 5, 425-426. See Appendix 2 for full text of
Nuremberg Code.
26 The Nuremberg Code, however, was not the first document to outline the obligations of researchers
conducting human clinical investigations. In fact, federal law in German already included such obligations
and prohibitions against unethical research but these laws were ignored during the Third Reich. See
Levine, supra note 5, at 69.
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Table 1: Influential Documents on Research Ethics
Year

Publication

Author

Description

1947

Nuremberg Code

Nuremberg judges

First major international code of
research conduct created after
Nuremberg trials of Nazi
physician/ researchers

1964

Declaration of

World Medical Association

Helsinki

Comprehensive ethical
guidelines for physicians
involved with research, last
updated in 2000

1979

Belmont Report

The National Commission for the
Protection of Human Subjects of

Report that identified key
principles for guiding human

Biomedical and Behavioral

research protection, including

Research from the Department of

respect for persons, beneficence,

Health, Education, and Welfare

justice'

The first principle of the Nuremberg Code states: "The voluntary consent of the human
subject is absolutely essential."28 The term "voluntary" is further elaborated:
This means that the person involved should have legal capacity
to give consent; should be so situated as to be able to exercise
free power of choice, without the intervention of any element of
force, fraud, deceit, duress, overreaching, or other ulterior form
of constraint or coercion; and should have sufficient knowledge
and comprehension of the elements of the subject matter
involved as to enable him to make an understanding and
enlightened decision.24

This principle, although well intentioned, is extremely overbroad because, taken literally, it
would prohibit all research involving those who are unable to consent including children and the
mentally disabled who are unable to give informed legal consent. The Code makes no exceptions
for proxy consent or consent for minors to be given by parents. Investigators, therefore, have
largely ignored this principle of Nuremberg Code and continued to conduct research using these
populations. Even though the authors may be admired for attempting to codify basic ethical
principles, the overall impact of the Nuremberg Code on actual research practices has been
minimal. One scholar also points out that "the very circumstances that gave the code its high

27

See Julie Rothstein Rosenbaum, Educating Researchers: Ethics and the Protection of Human Research
Participants, 31 CR1T. Care Med. No. 3, Suppl. At SI62 (2003).
28 See Nuremberg Code, supra note 25.
29 See id.
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moral standing - the horrors that surrounded its origins - partly account for its relative lack of
influence in the postwar years: ordinary researchers found it hard to believe that the code need
be applied to their own work/'10
In response to the overly restrictive Nuremberg code, the World Medical Association
adopted the Declaration of Helsinki in 1964.31 The Declaration emphasizes the importance of
freely given informed consent by research subjects, but it parts with the Nuremberg Code in an
important way:
In case of legal incompetence, informed consent should be
obtained from the legal guardian in accordance with national
legislation. Where physical or mental incapacity makes it
impossible to obtain informed consent, or when the subject is a
minor, permission from the responsible relative replaces that of
the subject in accordance with national legislation.1'

The Declaration of Helsinki implicitly acknowledges that research on groups who are unable to
give consent is necessary to advance medical care for these groups and provides a method for
obtaining proxy consent. It serves as a more practical guide to researchers and tries to alleviate
the problem of the therapeutic orphan. Nevertheless, even after the Declaration of Helsinki was
written, pediatric research was rare in the United States because the legal status of proxy consent
remained uncertain.
Another important feature of the Declaration of Helsinki was its division of research into
therapeutic and non-therapeutic categories. The 1975 revised Declaration divides research into
"Medical Research Combined with Professional Care (Clinical Research)" and "Nontherapeutic
Biomedical Research Involving Human Subjects (Nonclinical Biomedical Research)." For the first
category of research (therapeutic research), the physicians can perform research "only to the
extent that medical research is justified by its potential diagnostic or therapeutic value for the

30 Kendall A. Desaulniers, Legislation to Protect the Decisionally Incapacitated Individual’s Participation
in Medical Research: Safety Net or Trap Door? 13 REGENT U.L.REV. 179, 182 (2000-2001).
31
See Human Experimentation: Code of Ethics of the World Medical Association, 2 BRIT. Med. J. 177
(1964). See also Declaration of Helsinki (1975), reprinted in Levine, supra note 5, 427-429. The
Declaration of Helsinki has been revised several times, most recently in 2000. See Appendix 3 for full text.
32 See Declaration of Helsinki, supra note 31, at 428, Part I. Basic Principles, No. 11.
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patient."33 In the non-therapeutic category, however, the subjects must be "healthy persons or
patients for whom the experimental design is not related to the patient's illness."34 The distinction
between therapeutic and non-therapeutic research has the unfortunate consequence of
prohibiting all placebo-controlled studies because the placebo arm is not of therapeutic value to
the patient, and using healthy control subjects for the placebo arm of a trial would yield no useful
information.34 Levine explains that the therapeutic/non-therapeutic distinction essentially
prohibits all research in pathogenesis, pathophysiology and epidemiology because these types of
studies usually will not have therapeutic value for the research subjects.3" Levine further clarifies
that every clinical trial has components that are not therapeutic, but to then classify the entire
protocol as therapeutic just because it has one therapeutic component results in the "fallacy of the
package deal."37 Non-therapeutic components of a protocol are commonly justified because the
protocol includes one or more therapeutic components. Levine provides some examples:
Such erroneous justifications in the recent past have been
frequent. In trials of thrombolytic therapy, repeated coronary
angiograms have been performed on patients who had clinical
indications for only one. Liver biopsies have been performed for
no reason other than to disguise treatment assignments in a
double-blind placebo-controlled trial. Repeated endoscopies
have been performed in a population of patients with peptic
ulcers who had clinical indications for no more than one.
Placebos have been administered by way of a catheter inserted
in the coronary artery. I do not want to be misunderstood as
saying that any of these procedures were unethical. I am simply
arguing that they should not be justified according to standards
developed for "therapeutic research."38

The Declaration of Helsinki was most recently revised in October 2000. Despite some changes
adopted in this sixth edition, the Declaration remains restrictive of placebo trials. In addition.

33 Id. at 429, Part II. Medical Research Combined with Professional Care (Clinical Research), No.6.
34 Id. at 429, Part III. Nontherapeutic Biomedical Research Involving Human Subjects (Nonclinical
Biomedical Research), No. 2.
35 Levine, supra note 5, at 9.
36 See id. See also Robert J. Levine, International Codes of Research Ethics: Current Controversies and the
Future, 35 Ind. L. Rev. 557, 560 (2002). See also Declaration of Helsinki, supra note 31, §§ II.6 and III 2.
37 Levine, supra note 36, at 560.
38 Id.

'
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although it removed the words "therapeutic" and "non-therapeutic," it still uses the distinction to
determine what research is permissible. "
Though they served as important advances in the conceptual framework for ethical
research, the Nuremberg Code (1947) and the Declaration of Helsinki (1964) were never legally
binding documents and were not able to halt the research abuses that were already underway
and continued until the 1970s such as the Tuskegee Syphilis Study and the Willowbrook School
study on children.41' The ethical codes of Nuremberg and Helsinki were not powerful enough to
stop the egregious devaluing of human life that these research studies exemplified. In the
aftermath of these studies, a modem code that was legally binding was needed to govern
research ethics and renew the public's trust in medical research.

The National Commission and Ethical Principles
The Department of Health, Education and Welfare (DHEW) published the first proposed
regulations on protection of human subjects in 1973. When the atrocities of the Tuskegee
experiments came to light. Congress held national hearings on human clinical research, and
eventually adopted the National Research Act of 1974 (Public Law 93-348), which created the
National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research [hereinafter "Commission"]. The Commission was to develop guidelines for ethical
research involving human subjects and make recommendations to the DHEW Secretary for the
application of these guidelines.41 Section 202(a)(1)(A) of the National Research Act specified that
the Commission should:

39 See id. at 559.
40 The Tuskegee Syphilis experiment began in 1932 and was designed to measure the results of untreated
syphilis in black males who were uneducated sharecroppers. The protocol in this trial included a placebo
arm where subjects were given aspirin instead of proven treatments for syphilis. Furthermore, the
researchers did not stop the trial and give subjects penicillin when it was discovered in the 1940s. The
study did not receive press attention until 1972. See supra notes 5-9 and accompanying text for discussion
of the Willowbrook studies.
41 See The National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research: Research Involving Children: Report and Recommendations. DHEW Publication No. (OS) 770004 at xvii, [hereinafter Report on Research Involving Children] Washington, D.C. (1977).

14

(i)

conduct a comprehensive investigation and study to
identify the basic ethical principles which should
underlie the conduct of biomedical and behavioral
research involving human subjects,

(ii)

develop guidelines which should be followed in such

(iii)

with such principles, and
make recommendations to the Secretary (I) for such

research to assure that it is conducted in accordance

administrative actions as may be appropriate to apply
such guidelines to biomedical and behavioral research
conducted or supported under programs administered
by the Secretary.. .42

The Commission published reports on human subject research from 1975-1978 and presented the
reports as recommendations to the DHEW Secretary as it was instructed.4' The Commission
addressed topics such as IRBs, research on the fetus and embryo, and research involving
children. The Commission was disbanded in 1978 but during its brief years of existence it made
valuable contributions to the discussions of research ethics and suggested possible regulatory
guidelines.
The Commission's Belmont Report: Ethical Principles and Guidelines for the Protection
of Human Subjects Research (1979) described three ethical principles that should guide research
involving human subjects: respect for persons, beneficence, and justice.

The first of these, respect

for persons, requires that individuals be treated as "autonomous agents" and also that "persons
with diminished autonomy and thus in need of protection are entitled to such protection."44 To
treat a person as an "autonomous agent" requires that the individual be left alone, even if doing
so may result in harm to that person, unless he/she consents to receive help or participate.4’
Furthermore, a person's actions should not be hindered unless they are clearly detrimental to
others.41' Certainly, not every person has the ability to act as an "autonomous agent" and it is this

42 Levine, supra note 5, at xii.

43 Importantly, the Commission explicitly repudiated the use of therapeutic and non-therapeutic categories
of research after using the distinction in its first report on research involving fetuses.
44 See The National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research: The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of
Research. DHEW Publication No. (OS) 78-0012 Washington, D.C. (1978) [hereinafter Belmont Report]
(text also available at <http://ohrp.osophs.dhhs.gov/humansubjects/guidance/belmont.htm>).
44 Levine, supra note 5, at 15.
46 See id. at 16.
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subset of people that require additional protections because without them, they are far more
likely to have their person disrespected/' Because research involving children involves persons
with diminished autonomy, children deserve extra protections when they participate in such
research.
The second ethical principle, beneficence, is understood to mean that the researcher
should maximize possible benefits and minimize possible harms.48 It is important to recognize
that this principle is more than simple non-maleficence; it also imposes a positive duty on the
researcher to maximize benefits and minimize harms. The Belmont Report recognizes that this is
not always a simple task and that researchers will need "to decide when it is justifiable to seek
certain benefits despite the risks involved, and when the benefits should be foregone because of
the risks."41' The Belmont Report allows the benefit to society to be considered in the equation
when balancing risks and potential benefits involved/11
Justice, the third basic principle, requires that subjects are chosen and treated fairly.
Justice is essential to "insure that certain individuals or classes of individuals - such as prisoners,
elderly people, or financially impoverished people - are not systematically selected or excluded,
unless there are scientifically or ethically valid reasons for doing so."51 This concept of justice is
meant to provide an equal distribution of the benefits and burdens that accompany research. The
Commission did not interpret justice in a utilitarian way to mean the greatest good for the
greatest number of people because this view ignores the idea that fairness requires extra
protections for vulnerable groups.52 The Commission concluded that:
persons having limited capacity to consent are vulnerable or
disadvantaged in ways that are morally relevant to their
involvement as subjects of research. Therefore, the principle of

47 Id. Levine argues: “The capacity of self-determination matures during a person’s life; some lose this
capacity partially or completely owing to illness or mental disability or in situations that severely restrict
liberty, such as prisons. Respect for the immature or the incapacitated may require one to offer protection
to them as they mature or while incapacitated.”
48 See Belmont Report, supra note 44.
49 See id.
50 See Declaration of Helsinki, supra note 31. See also Desaulniers, supra note 30, at 203.
51 See Belmont Report, supra note 44.
52 Levine, supra note 5, at 18.

'
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justice is interpreted as requiring that we facilitate activities that
are designed to yield direct benefit to the subjects..."'

These three principles of respect for persons, beneficence and justice have provided the
ethical framework for human clinical research, and as noted by the Commission, these principles
require additional safety measures to protect vulnerable populations involved in research. The
Commission's reports and suggestions, which were later adapted and adopted into the Code of
Federal Regulations, rely heavily on the ethical principles.
In 1980, DHEW was restructured; education became a separate department, and what
remained of DHEW became the Department of Health and Human Services (DHHS). Shortly
thereafter, in 1981, DHHS published federal regulations on the protection of human subjects that
were mostly an adoption of the Commission's suggestions. These initial federal regulations did
not include special regulations for children, but regulations for children were finally approved
two years later in 1983.44
Although the Code of Federal Regulations attempts to provide boundaries between
acceptable and unacceptable research, there will always be research protocols that do not fall
neatly into these categories. It is precisely when the regulations do not provide clear answers
regarding the acceptability of a particular research protocol that the three ethical principles
become even more important; they should serve as guidance when the regulations are
ambiguous.

Part III: Federal Regulations
Additional Protections for Children Involved as Subjects in Research:
The Commission's report, Research Involving Children (1977), made recommendations
that allow children to be used in research, yet still protect them adequately from harm. The
recommendations served as the basis for the Code of Federal Regulations (CFR) Subpart D:

53 See Belmont Report, supra note 44. See also LEVINE, supra note 5, at 236.
54 LEVINE, supra note 5, at xii. See also Report on Research Involving Children, supra note 41.
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Additional Protections for Children Involved as Subjects in Research (1983). Unlike the
Nuremberg Code and the Declaration of Helsinki, the regulations are legally binding, yet they
are not without their own flaws. The main purpose of the Subpart D is to provide children, as
members of a population considered vulnerable, with additional safeguards. The section divides
research involving children into four categories, each of which has different requirements for
approval. (See Table 2.) Section 46.403 further requires that IRBs only approve research that
satisfies the requirements set forth in the remainder of Subpart D.
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Table 2: Federal Regulations for Research Involving Children

Federal
Regulation
Section

Risk Posed by
the
Intervention or
Procedure

Additional Requirements for Protocol
Approval

45 CFR §46.404

No greater than

No additional requirements

(*A11 require IRB approval, child's assent” and
permission by parent or guardian^)

minimal risk
45 CFR §46.405

Greater than

1.

Risk is justified by the anticipated benefit to each

2.

Anticipated benefit to each subject is at least as

minimal risk with
prospect of direct

subject

benefit to subject

favorable as that presented by available
alternative approaches

45 CFR §46.406

Greater than
minimal risk with

1.

Risk represents a minor increase over minimal
risk

no prospect of

2.

Intervention or procedure presents experiences to
the child that are reasonably commensurate with

direct benefit to
subject

those in the child's actual or expected medical,
dental, psychological, social or educational
situations
3.

The study is likely to yield generalizable
knowledge about the child's disorder or condition
that is of vital importance for the understanding
or amelioration of the disorder or condition

45 CFR §46.407

Research not

1.

IRB finds that the research presents a reasonable

otherwise

opportunity to further the understanding,

approvable

prevention, or alleviation of a serious problem
affecting the health or welfare of children
2.

Approval of the Secretary of DHHS after
consultation with a panel of experts in pertinent
fields, and following opportunity for public
review and comment’

The drafters of the regulation, following the lead of the Commission, refrained from
using the distinction between therapeutic/non-therapeutic research and thereby avoided the
"fallacy of the package deal" that is created with the Declaration of Helsinki language and others

55 45 CFR §46.408. Requirements for permission by parents or guardians and for assent by children: In
addition to the determinations required under other applicable sections of this subpart, the IRB shall
determine that adequate provisions are made for soliciting the assent of the children, when in the judgment
of the IRB the children are capable of providing assent. In determining whether children are capable of
assenting, the IRB shall take into account the ages, maturity, and psychological state of the children
involved.
56 Permission from one parent or guardian is acceptable for research covered by §§ 46.404 and 46.405, but
where research is covered by §§ 46.406 and 46.407 both parents must give their permission unless one
parent is deceased, unknown, incompetent, or not reasonably available, or when only one parent has legal
responsibility for the care and custody of the child. See 45 CFR §46.408.
57 45 CFR §46.404-7. See also Jeffrey P. Burns, Research in Children, 31 CRIT. CARE Med. 2003 No. 3
(Suppl.) at SI34.

-
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who rely on such a distinction."'1 Rather than analyzing the overall risk posed by a research
protocol, the risk posed by each individual intervention or procedure in the protocol is assessed.
These risks are weighed against possible benefits caused by those same interventions or
procedures. This assessment prevents the error of justifying an extremely risky intervention
simply because it is part of a protocol deemed to have large overall benefits. An important caveat
to the risk/benefit calculation for each study is that the benefits can only encompass the health
consequences of the study's interventions and procedures. Economic incentives such as direct
payments, free medical treatment, free medications or diagnostic tests are not included as
benefits because using economic incentives in the risk/benefit analysis or including them as
benefits in the informed consent is viewed as starting a slippery slope toward undue inducement.

§404: No Greater than Minimal Risk
The first category of research is that which involves interventions or procedures that pose
nothing greater than minimal risk to a research subject who may be either a healthy child or a
child with an illness. For this research, the criteria for approval are essentially the same as those
required for all human subjects including adults or non-vulnerable populations. The only
additional requirements for a pediatric population are that the child's assent be obtained (if
possible) and that a parent or guardian gives permission for the child's participation in the
study.Because the idea of "minimal risk" is subject to multiple interpretations, the drafters of
the regulations attempted to clarify to the words by defining that minimal risk "means that the
risks of harm anticipated in the proposed research are not greater, considering probability and
magnitude, than those ordinarily encountered in daily life or during the performance of routine
physical or psychological examination or tests.The idea behind the minimal risk threshold is
that it is a socially permissible level of risk to which parents would normally permit their
58

See Levine, supra note 36, at 560 and accompanying text.
59 45 CFR §46.404 and §46.402 (b) Assent means a child's affirmative agreement to participate in research.
Mere failure to object should not, absent affirmative agreement, be construed as assent, (c) Permission
means the agreement of parent(s) or guardian to the participation of their child or ward in research.
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children to be exposed in non-research settings. The National Commission provided some
examples of interventions that easily fall within this category: routine immunizations, modest
changes in diet or schedule, physical examination, obtaining blood and urine specimens, and
developmental assessments.M It is important to remember that for protocols that fall under this
category, it does not make any difference whether the intervention has the potential to benefit the
subject or not, or whether the child is healthy or not. As long as the risk posed by the
intervention is no more than minimal risk, there are no additional requirements for review and
acceptability.

Defining Minimal Risk
There are several problems with the definition of minimal risk provided in the Code of
Federal Regulations but many of these can be reconciled by examining the Commission's report
and the principles of respects for persons, beneficence and justice on which the regulations are
based. First, the regulations do not explicitly indicate whose daily life should be used as a
standard, and certainly not all members of the research group are exposed to the same risks of
harm in their daily lives. For example, a child growing up in extreme poverty may encounter a
daily risk of malnourishment that is not experienced by her wealthier counterpart. A child
growing up in a war torn nation, or a country plagued by AIDS will definitely encounter greater
risks in daily life than a child growing up in a more stable environment.62 Some argue that the
"daily life" requirement should be based on the average child within that population. Others
argue that the acceptable risk level should be based on the daily risks encountered by healthy
children in a stable environment. The definition of minimal risk in the federal regulations differs
in one important respect to the definition first proposed in the National Commission's

60 45 CFR §46.102(g)
61 See Report on Research Involving Children, supra note 41 at xx-xxi.
62 See, e.g., Burns supra note 57, at S134. Burns asserts: “In particular, if one adopts a relative
interpretation of minimal risk, then some children whose daily routine exposes them to relatively higher
risks in theory could also be the subjects of research in which the risk exposure was, therefore,
proportionally higher than would be approved for a child from a more protected or advantaged
background.”
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recommendations. The Commission stated: "Minimal risk is the probability and magnitude of
physical or psychological harm that is normally encountered in the daily lives, or in the routine
medical or psychological examination, of healthy children,"63 The Commission's intent was to
define the minimal risk threshold based on a healthy child but the federal regulations are
ambiguous. The Commission also provided specific examples of procedures that they considered
to be no more than minimal risk but these specific examples were excluded from the regulations,
thereby leaving the acceptability of some of these more common procedures to the individual
judgment of the IRBs.
Although the federal regulations do not explicitly define minimal risk to be based on the
daily risks encountered by healthy children, it is clear that the Commission's report intended it to
be defined in this absolute way. Consider, for a moment, the possibility that the daily risks in the
federal regulations are interpreted as being relative and not absolute. Certainly, there are
children exposed to abnormally high levels of risk, but to use their daily experiences as the
threshold of daily risk would unjustly subject them to higher risks than other children.'4 This
type of justification for a high risk protocol is reminiscent of the Willowbrook studies where
children who were exposed to an abnormally high risk of contracting hepatitis were then given
hepatitis because it was considered to be a risk to which they were already exposed.
Undoubtedly, the federal regulations were written to prohibit this type of research, not to protect
it. Therefore, daily risks, as written in the regulations, must be interpreted as risks that a healthy
child in a stable environment encounters.
The National Human Research Protections Advisory Committee (NHRPAC) Children's
Workgroup was formed in 2000 and was charged with providing advice and recommendations
on human subjects protection to the Office for Human Research Protections (OHRP). They

63 See Report on Research Involving Children, supra note 41, at xx (emphasis added). It is interesting to
note that the Commission offered different definitions of minimal risk in several of its reports in an effort to
express their view that the threshold should be different for different populations. This subtly was lost
when the drafters of the federal regulations provided a single definition of minimal risk for all human
subject populations. (Personal Communication, Robert J. Levine, January 2004).
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issued a report to clarify the definitions of minimal risk and minor increase over minimal risk. In
the report they specifically denied that minimal risk should be a variable standard based on a
particular child's circumstance and defined minimal risk to be the level of risk associated with
the daily activities of a "normal, healthy, average child.'"* Furthermore, the report states that
"indexing the definition of minimal risk to the socially allowable risks to which normal, average
children are exposed routinely should take into account the differing risks experienced by
children of different ages."*
Certainly, this argument is not meant to prohibit children exposed to abnormally high
risks from ever participating in research; it simply asserts that subjecting them to their high
baseline risks cannot be classified as minimal. The fact that these children face abnormally high
risks is not a morally relevant distinction that justifies protecting them less when they participate
in human clinical trials. To use a relative standard for minimal risk would violate the principle of
justice for these children. They would be subject to an unequal distribution of the burdens of
research involving human participants because riskier studies could be performed with them
whereas they could not be performed with healthier children.
The second difficulty with the definition of minimal risk is that it considers the
"probability and magnitude" of possible harm, but it does not provide a framework with which
to judge what are acceptable probabilities and magnitudes of harm.

To decide what is an

appropriately low level of probability of harm or degree of magnitude is not an easy task. The
evaluation requires careful balancing and normative assessments since sometimes a low
probability of substantial harm might be approved whereas a high likelihood of a more moderate
harm may not.h7 Because the federal regulations do not suggest a way to judge acceptable levels
of harm, the IRBs are left to make the decisions on their own. The federal regulations do not offer

64 See Loretta M. Kopelman, Children as Research Subjects: A Dilemma, 25 J. OF MED. & PHIL. No. 6,
745, 754 (2000).
65 Clarifying Specific Portion of 45 CFR 46 Subpart D that Governs Children’s Research, National Human
Research Protections Advisory Committee, Children’s Workgroup Report, [hereinafter Workgroup Report]
(text available at <http://ohrp.osophs.dhhs.gov/nhrpac/documents/nhrpacl6.pdf>.
66 Id.
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any examples of acceptable or unacceptable harms as a reference point for the IRBs. Perhaps the
local IRBs are best suited to make this assessment on a case-by-case basis, but one might also
argue that leaving too much power in the hands of overburdened IRBs without adequate
guidance is a recipe for inconsistency and a set up for disaster.

§405: Interventions with Prospect of Direct Benefit to Subject
The second category includes procedures or interventions that have the potential to
benefit the individual subject directly. In these cases, it does not matter if the intervention poses
greater than minimal risk to the subject and the minimal risk evaluation is not needed in the
analysis of these cases.

Because this class of interventions must have the prospect of directly

benefiting the subjects, it will generally involve a child who is not the average healthy child in a
stable environment.'1* In such cases, the research protocol has the added requirements of showing
that the risk posed to the subjects is justified by the anticipated benefit, and that the anticipated
benefit is at least as favorable to the subjects as that presented by available alternatives.**
An example of a research protocol that easily falls into this category is a study with a new
chemotherapeutic agent for leukemia. The new drug may pose a significant risk to the potential
subjects, but as long as the anticipated benefits are also high, and the expected benefits from the
agent are at least as high as the current available alternative medication, then the trial would be
appropriately approved. Importantly, any control arm of this study would need to receive the
current available alternative medication and not a placebo in order for the trial to be approved.
Although it may be subject to more controversy than the above example, there are
situations when determining the high level of daily risks to which some populations are exposed
and using that level of risk in a study is absolutely essential to studying potentially beneficial

67 See Kopelman supra note 64, at 753.
68 But cf. Bruce Gordon et. al.. The Use of Normal Children as Participants in Research on Therapy, IRB:
Ethics & human Research, 5-8 (May-June 1996). This study involved using siblings of ill children in a
protocol that involved more than minimal risk procedures. The healthy siblings were viewed as gaining a
direct psychological benefit from participating in the research protocol (because they could potentially help
keep their ill sibling alive) and therefore, were able to participate under §405.
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interventions for those populations. While justifying higher risks for a specific population may
tread on dangerous ground, there is a moral imperative to do so because without such research,
there will be fewer developments in the ways in which those exact same higher risks could be
lowered. It would not be possible to study a particular risk factor and try to find a way to
alleviate it in a practical manner unless the protocol continued to expose the population to their
normal daily risks for the duration of the study. In order for the results of a study to be practically
applicable to the population, the intervention must be tested within the population's normal
environment and daily risk exposures. In these cases, the principle of justice demands that
adequate research studies are carried out with these populations in order to help lower the risks
to which they are exposed.
A real-life case example is provided by the placebo-controlled trials of the "shortduration" AZT therapy in preventing perinatal transmission of HIV in developing countries.
Some opponents of the research argued that the research subjects were unjustly treated in that
they received a sub-standard level of care during that trial. True, the subjects did not receive the
best proven therapeutic method available in industrialized countries (076 regimen), but the
interventions they did receive had the possibility of being beneficial in their specific situation. To
ride an ethical high horse about why research that is not acceptable for a child in America should
also not be acceptable for a child in a disease-torn country does a disservice to the child who is
subjected to the increased risks already. That child has the potential to benefit from the research
far more than the child in America, and the risk/benefit analysis needs to take this into account
in the determination of what is acceptable research. Levine argues that to use the 076 regimen in
these countries would have required an almost impossible revision of their perinatal customs
including requiring women to seek prenatal care much earlier than they are accustomed, using
intravenous medications, and finding a safe alternative to breast feeding for babies of HIV-

69

See 45 CFR §46.405.
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infected mothers in countries with no infant formula and contaminated water supplies."

Levine

asserts:
In summary, it is clear that the 076 regimen of AZT cannot be
made available to most HIV-infected pregnant women in the
resource poor countries now or in the foreseeable future. This is
the main reason that it is essential to find methods to reduce the
rate of perinatal transmission of HIV that are within the financial
reach of the resource poor countries. Finding these methods was
the primary justification for conducting the clinical trials of the
short duration regimen of AZT. The cost of the AZT in this
regimen was about ten percent of that of the 076 regiment.
Moreover, there was no need for intravenous therapy or
administration of the drug to the babies. At the time the trials
began, it seemed likely that two of the countries could afford to
provide the short duration regimen if it proved effective; there
was also a commitment from international agencies to assist the
other resource poor countries in securing and providing the
drug.71

Another example provides additional clarity: If a child is already exposed to a
contaminated water supply and there are no resources to improve the supply, a study to see if
partially purified water alleviates some disease that is usually caused by the impure water should
be acceptable.72 Such a study submits the children to a higher level of risk than an average
healthy child, but it has the potential to benefit the subjects in a way that healthy children would
not benefit. To expose the children to improperly cooked meat or another type of risk to which
they are not already exposed would not be permissible, even though it poses a similar level of risk
as the impure water, because the risk is not something already experienced by the child.
Furthermore, taking a child with a healthy water supply and submitting her to impure water for
the purpose of the research would also not be permissible under §405 because she does not gain
any direct benefit from the intervention. Although this scenario may seem far-fetched because
pure water is taken for granted in an industrialized country like America, the hypothetical is

70 See Levine supra note 36, at 563.
71 Id. See also Council for International Organizations of Medical Sciences, International Ethical
Guidelines for Biomedical Research Involving Human Subjects, (Geneva 2002).
72 One might argue that in each of these cases the children are not truly exposed to a risky intervention but
instead something of potential benefit is withheld from them. The withheld benefit is something to which
they did not previously have access and will likely not have access to in the future. True, the regulations do
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analogous to a recent study involving lead abatement interventions to reduce lead poisoning in
children.

Grimes v. Kennedy Krieger Institute: §405 Gone Awry ?
In 1993, the Environmental Protection Agency awarded a research grant to the Kennedy
Krieger Institute (KKI), a research institution affiliated with Johns Hopkins University, entitled:
"Evaluation of Efficacy of Residential Lead Based Paint Repair and Maintenance Interventions."71
The study was designed to compare comprehensive lead paint abatement with lesscomprehensive repair and maintenance interventions that would possibly be more cost effective.
There were five arms to the study, three of which were interventions with different levels of lead
abatement and two of which were controls. Researchers used houses that were built before 1941
or had documented lead based paint present for the intervention groups. Each of these three
groups received a different amount of money in either grants or loans for different levels of
repairs and maintenance aimed at reducing lead within the house. Groups four and five
consisted of houses that were already lead abated or houses that were built after 1980 when lead
paint was no longer used.
The subjects enrolled in the study were the children of the families that rented the homes.
Some of the children were already living in the homes included in the study, but importantly,
some of the families moved to the houses during the study because participation in the study was
what allowed the properties to be on the rental market.4 Investigators recruited families with
young children to occupy the homes. Parents permitted their children to participate in the study
and agreed to submit them to as many as eight or nine blood tests within the following two years.

not specifically address this issue. But, in this hypothetical, one can imagine a scenario where the method
of partially purifying water exposes the children to an additional degree of risk.
73 Grimes v. Kennedy Krieger Institute, Inc., 782 A.2d 807, 819 (Md. 2001). See also Hazel Glenn Beh,
The Role ofIRBs in Protecting Human Subjects: Are We Really Ready to Fix a Broken System? 26 Law &

and Psychol.

Rev.

1,4 (2002).

74 See Beh supra note 73, at 5-6. Landlords participating in the study attempted to rent to families with
young children and in return, KKI helped the landlords apply for grants for lead abatement.
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to allow their homes to be tested for lead periodically over that time period and to answer
questionnaires/"
The Johns Hopkins University Joint Committee on Clinical Investigations, the
institution's IRB, initially questioned whether the use of healthy control subjects in non leadpaint homes was permissible under the federal regulations given that there was no real
therapeutic benefit to these control subjects (and therefore, the intervention could not be
categorized under §405)."" The IRB therefore suggested that the consent form be changed to
identify some additional benefits that all subjects would receive by participating in the study."
The IRB suggested that the consent form indicate that the control group was being studied to
determine the amount of lead exposure these children would have outside the house, and
therefore, these children would also receive some benefit from the study interventions.
Two of the families in the study later sued KKI when their children were found to have
increased levels of lead. The families alleged that KKI discovered lead hazards in their respective
homes and, having a duty to notify them, failed to warn in a timely manner or otherwise act to
prevent the children's exposure to the known presence of lead. Additionally, they alleged that
they were not fully informed of the risks of the research.s The trial court in Baltimore granted
summary judgment in favor of KKI on the ground that KKI did not owe a legal duty to the
plaintiffs to warn them of the presence of lead dust but the appellate court vacated the lower
court's ruling and remanded for a trial. Although the appellate court determined that KKI may
have owed a legal duty to the plaintiffs and therefore, the decision could not be made on
summary judgment, the appellate court overstepped the limited question presented by the case
and made several statements in its opinion that are simply not in line with a reasonable
interpretation of the federal regulations.

75 Id. at 7.
76 The IRB failed to appreciate that the control arms (houses without lead) did not pose greater than
minimal risk to the subjects and therefore was justifiable under §404. Furthermore, if all the children are
viewed as being “at-risk” for lead exposure, then the subjects in the control arms, having been removed
from lead risks in the home, did benefit from the intervention. See Lainie F. Ross, In Defense of the
Hopkins Lead Abatement Studies, 30 J.L. Med & ETHICS 50, 52 (2002).
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From the facts available to the appellate court, it does appear that KKI's protocol violated
several of the federal regulations as well as basic ethical norms. Some of the more egregious
errors included: (1) enticing healthy controls to move into lead exposed housing (violation of
§404 because lead exposure is more than minimal risk79); (2) rephrasing the protocol (at the IRB's
suggestion) so that healthy controls in groups four and five were supposed to obtain some benefit
from the interventions even though it seemed unlikely that they were being exposed to lead
outside the home (this was simply a disingenuous representation of the study); (3) inadequate
consent forms (violation of requirements for informed consent in §46.116); and (4) a several
month delay in reporting the lead levels to the families (violation of a promise made by KKI to
the subjects). Although these violations of the federal regulations and unethical acts can hardly
be excused, it is important to note that the Grimes Court also erred in several respects.*"
The Court made the pervasive mistake of classifying the research into "therapeutic" and
"non-therapeutic" categories and it deemed the research study here to be "non-therapeutic." By
adopting the "package deal" the court denied that any of the interventions could have a direct
benefit to any of the subjects. This in fact was not the case. The children who were already living
in the houses with high lead levels did receive direct benefit by obtaining a degree of lead
abatement in their houses.*1 The Court stated: "We hold that in Maryland, a parent, appropriate
relative, or other applicable surrogate, cannot consent to the participation or other person under
legal disability in nontherapeutic research or studies in which there is any risk of injury or
damage to the health of the subject." The Court later explained this statement by insisting that it

77 See Beh supra note 73, at 8-9.
78 See Grimes, 782 A.2d at 818.
79 Even if being “at-risk” of lead poisoning qualifies as a “condition or disorder” §406 may have been
violated because the risk of living in lead contaminated housing may be more than minor increase over
minimal risk.
80 See Grimes, 782 A.2d at 860. J. Raker concurred in result only, stating: “I cannot join the majority’s
sweeping factual determinations that...IRBs are not sufficiently objective to regulate the ethics of
experimental research; that it is never in the best interest of any child to be placed in a nontherapeutic
research study that might be hazardous to the child’s health; that there was no therapeutic value of the
research for the child subjects involved; that the research did not comply with applicable regulations; or
that there was more than a minimal risk involved in this study.”
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meant "minimal risk" when it stated "any risk,"82 but even given this clarification, the Court
seems to permit only §404 research and completely deny §405 research primarily because it fails
to recognize that the use of the nontherapeutic label causes it to reject the entire protocol instead
of weighing the interventions' potential benefits against the risks. The Court disregards that it is
permissible to approve nonbeneficial procedures according to §405.
In other words, if the protocol had included only houses that already had children living
in them, every child in the three intervention groups would have received some benefit from
being part of the trial because their lead exposure was likely to decrease, and therefore, the trial
should be deemed acceptable under §405. Furthermore, the children in groups four and five
would not be subjected to the risk of lead and only required to have periodic venipunctures, an
intervention while not directly beneficial, poses only minimal risk and falls under the category of
procedures that are approvable under §404. From the statements made by the Grimes Court,
however, it appears that they would not accept even this limited study because the continued
exposure to some lead for the intervention groups is more than a minimal risk. One might object
to this more limited study because the children in the intervention groups are not receiving fully
lead abated houses, but similar to the short-course AZT trials, this population of children does
not have realistic access to fully lead abated houses, so certainly to help them a little is better than
no help at all. Unfortunately, the Grimes Court overstepped the limited question presented to it
and its opinion, taken to its fullest, would not permit even this hypothetical study where no
children are actively recruited to live in lead contaminated houses.81
The Grimes opinion should raise warning bells that if the federal regulations are not
explicated further, either in the federal regulations themselves, or by an authoritative

81 In fact, the partial lead abatement interventions were so effective that the program has been replicated in
13 other cities. See Robert M. Nelson, Nontherapeutic Research, Minimal Risk, and the Kennedy Krieger
Lead Abatement Study, IRB: ETHICS & HUMAN RESEARCH, 7 (Nov-Dec 2001).
82
See Ross, supra note 76, at 51.
83 This is an important distinction that sets it apart from the Willowbrook studies. Even if the prevalence of
lead-tainted houses in the Baltimore area were 85%, it would not be permissible to actively rent previously
empty houses in the study to families with children. This is analogous to the situation in Willowbrook
where the children living in the house had an 85% risk of contracting hepatitis. The high baseline risk does
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governmental body, mistakes in interpretation will lead to results not intended by the National
Commission or the drafters of the regulations.

§406: Interventions with No Prospect of Direct Benefit to Subject
The third category involves interventions or procedures with no prospect of direct
benefit to the subject.

For these types of studies, the intervention must present only a minor

increase over minimal risk to the subject, and the study must be likely to yield knowledge about
the child's disorder or condition that is of vital importance for the understanding or amelioration
of the disorder or condition. Furthermore, the intervention or procedure must present
experiences to the subjects that are reasonably commensurate with those experiences inherent to
their actual or expected medical, dental, psychological, social or educational situations.^ The
commensurability requirement exists because children who have had a particular intervention
previously are better able to understand what is being asked of them and therefore, their assent
to participate in the study will be better informed."’ The questions of what constitutes a "minor
increase" above minimal risk, and what is meant by "disorder or condition" and "reasonably
commensurate" have produced considerable disagreement and serve as another source of
differing interpretations of the regulations.
A research protocol that might fall within this category is a trial that takes a child with
leukemia and subjects her to one additional bone marrow aspirate in order to obtain information
about the disease course, but information that is not intended to benefit this particular child. It is
imaginable that the child with leukemia has already had a bone marrow aspirate and that
another aspirate would be reasonably commensurate with her actual experience so that if she
assents to participate, her assent is more informed than a child who has never experienced a bone
marrow aspirate. Furthermore, it is imaginable that such a research study could be designed to

not give the researchers the right to turn a high risk into a definite risk (either living in a lead contaminated
house or contracting hepatitis) for a particular child.
84 See 45 CFR §46.406.
83 Levine, supra note 5, at 248.
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yield generalizable knowledge about leukemia that is of vital importance for its amelioration, and
therefore such a trial would fulfill the requirements set by §406. In this hypothetical case, one
additional bone marrow aspirate is viewed as only a minor increase over minimal risk, but what
if the protocol called for two? Three? Ten? When is the threshold exceeded? Some might argue
that it is not possible to set a threshold - that it is an instinctual "gut feeling" that causes
reviewers to know when the limit has been exceeded. But surely this type of "I know it when I
see it" standard that the Supreme Court has used for recognizing pornography cannot be
invoked when errors in judgment potentially expose children to real danger.3'’ IRBs would be
hard pressed to find a public willing to accept such a subjective interpretation of §406.

Defining Minor Increase

The NHRPAC Children's Workgroup Report provided some insight into the definition of
minor increase over minimal risk. The group concluded that minimal risk itself should be an
absolute standard but that "minor increase over minimal risk" is a relative standard. They
acknowledged that the concept of commensurability is crucial to allow the child and parents to
have a point of reference from which to make their decision about participation. The Workgroup
report included lists of specific interventions and how they thought those interventions should be
classified. (See Tables 3 and 4.) Nevertheless, these recommendations are not universally agreed
upon and local IRBs will differ on their decisions of whether a particular research protocol is
acceptable or not. Some examples of what has been approved by Yale's IRB as presenting minor
increases above minimal risk include bone marrow aspirations in children with leukemia, single
additional spinal taps in adolescents who have already had at least one for a neurological
disorder, and administration of yohimbine in order to gain information about the pathogenesis of
a neurological disorder. This IRB rejected a proposal to do left heart catheterizations on children
at risk for the development of cardiac hemosiderosis.3'

86 See Jacobellis v. Ohio, 378 U.S. 184, 197 (1964) (6-3 decision) (Stewart, J., concurring).
0
Levine, supra note 5, at 249.
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Table 3: Common Procedures and Category of Risk33

Procedure*

Routine history taking

Minimal
Risk

Minor Increase
Over Minimal

More than a Minor
Increase over
Minimal

X

Venipuncture/fingerstick/heelstick

X

Urine collection via bag

X
X

Urine collection via catheter

X

Urine collection via suprapubic tap
Chest xray

X

Bone density test

X

Wrist xray for bone age

X
X

Lumbar puncture
Collection of saliva

X

Collection of small sample of hair

X

Vision testing

X

Hearing testing

X

Complete neurological exam

X

Oral glucose tolerance test

X

Skin punch biopsy w/topical pain

X

relief
Bone marrow aspirate w/topical pain

X

relief
Organ biopsy

X

Standard psychological tests

X

Classroom observation

X

* The category of risk is for a single procedure. Multiple or repetitive procedures are likely to
affect the level of risk.

88

Workgroup Report, supra note 65.

'
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Table 4: Interpreting Level of Risk in Common Procedures89
Procedure

Determinants of Level of Risk

Indwelling heparin lock catheter

The level of risk may range from minimal to more than a
minor increase over minimal depending on: age of the child,
length of time catheter will be in place, number and volume
of samples, and setting of the research

Single SC or IM injection

The level of risk of a single injection may range from minimal
to more than a minor increase over minimal depending on
the substance injected

Nasogastric tube insertion

Generally minor increase over minimal risk but should be
commensurate with prior experience of the child in order to
provide adequate assent and permission

Small amount of additional

Generally minor increase over minimal risk but must take

tissue obtained at surgery

into account any increased operative time, the specific organ
or tissue, and the likelihood of bleeding and infection
If no sedation - generally minimal

MRI

If procedural sedation - generally minor increase over
minimal. Intubation in the appropriate setting may decrease
potential risks for certain children and its possible use should
be considered on a case by case and proposal by proposal
basis.
Psychological test

Generally minimal if performed under standardized

/survey/ interview/observation

conditions but the level of risk may increase depending on
the sensitive nature of questions, the possibility to trigger
unpleasant memories or emotions, and the length of the
instrument or observation

One of the problems with the §406 requirements is that it is very difficult, if not
impossible, to generate any control data with healthy children for these types of studies. In the
leukemia example above, it would not be permissible to subject a healthy child to a bone marrow
aspirate because it is a procedure that is not reasonably commensurate with the child's actual or
expected situation. Furthermore, §406 presupposes a clear line between a child with a disease
and a child who is healthy. As was demonstrated through the examples for §405 research, the
line is not always well demarcated because the more "at-risk" a population is, the more it may be
considered unhealthy. In fact, the NHRPAC Workgroup defined the concept of "disorder or
condition" rather broadly:
We interpret the concept of disorder or condition as relating to a
specific characteristic which describes a group of children, a
physical, social, psychological, or neuro-developmental
condition affecting children, or the risk of certain children

89 Id.
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developing a disease in the future based on diagnostic testing or
physical examination. Thus, for example, prematurity, infancy,
adolescence, poverty, living in a compromised physical
environment, institutionalization, or having a genetic
predisposition to future illness are some disorders or conditions
of children that can, under the appropriate circumstances,
warrant permissible research that presents levels of risks that are
a minor increase over minimal without the prospect of direct
benefit."’

The NHRPAC definition, therefore, seems to classify the risk of developing a disease as a
disorder and therefore broadens this category of research widely. One might wonder, then,
would the NHRPAC Workgroup permit children in the lead abatement study who have normal
lead levels but are at risk for developing lead poisoning simply because they lived in an area of
Baltimore where the prevalence of living in a lead-tainted home is very high, to be enrolled in a
study that presented a minor increase over minimal risk without any intervention that could
provide direct benefit to the subjects (i.e. the recruitment of children from the area to move into
the homes participating in the study)? The Workgroup provided an example of children who
have a predisposition to diabetes because they are obese being enrolled in a study that used
various procedures to assess insulin resistance." Although the risks posed by the interventions
would not be minimal because they are greater than those risks normal, healthy, average children
encounter, the study could be approved under §406 because the interventions posed only a minor
increase over minimal risk, the study would be likely to yield generalizable knowledge of vital
importance about the development of diabetes or pathophysiology of obesity, the interventions
performed were commensurate with the expected experience of the subjects, and the site for the
study and skill of the investigator were appropriate. The NHRPAC Workgroup meant to define
disorder or condition more concretely, but their example reveals how the line between healthy
children and children with disorders or conditions is very difficult to draw. For example, are
children with a body mass index of 29.9 at-risk for diabetes and therefore qualify as having a

90 Id.
91 But cf infra notes 93-95 and accompanying text.
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"condition"?v2 What definition of obesity should be used? When do healthy populations become
"at-risk"? The NHRPAC Workgroup's expansive definition of condition or disorder will
definitely engender debate, but certainly such a definition does allow access to more control data
as the "at-risk" children can serve as "control" subjects in many studies. It is important to
recognize though, that as the NHRPAC Workgroup's definition makes research using "control"
subjects easier, it does so at the expense of the commensurability safeguard, because these
children are less likely to fully understand whether the intervention in the protocol is similar to
an actual or expected situation.
Stephanie Amiel, a Yale pediatric endocrinologist studying diabetes, completed a study
where "normal controls" were admitted for a 48-hour hospital stay in order to allow a 24-hour
blood hormone level profile through an intravenous cannula, plus a 4-hour hormone sensitivity
test through an additional intravenous cannula.11 This study could not be justified as presenting
no more than minimal risk because the psychological effects of a two-day hospital stay were
unknown.4 The "normal controls" were actually siblings of diabetic children and were thus
judged to have a "condition or disorder" thereby permitting review under §406. The Yale IRB
approved the study under §406 because it presented only a minor increase above minimal risk.
In retrospect, the only harm actually suffered by the control subjects seems to have been
uncomfortable IV sites and boredom, so perhaps the study could have in fact been approved
under §404 as causing no more than minimal risk, but at the time approval was sought the risks
could not have been so easily calculated.
In contrast, the National Institute of Child Health and Human Development (NICHD),
part of the National Institutes of Health (NIH), began a study to determine population
differences in insulin sensitivity, resting energy expenditure, and body composition of obese
children and children of obese parents in 1996 which was subsequently terminated by the OHRP

92 The current definition for obesity is a body mass index greater than 30. A body mass index between 25.0
and 29.9 is considered overweight.
93
See Stephanie A. Amiel, Pediatric Research on Diabetes: The Problem of Hospitalizing Youthful
Subjects, IRB: A REVIEW OF Human SUBJECTS RESEARCH, 4-5 (Jan-Feb 1985).
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in 2000J The trial had enrolled over 190 children aged 6 to 10 before it was terminated. The
investigators had planned to follow the children for 15 years and collect blood samples,
radiographs and magnetic resonance imaging scans all of which were considered to be minimal
risk by the original review board that approved the study.

Four years later, however, the OHRP

stated that the interventions posed more than minimal risk'h and did not present the prospect of
direct benefit to the subjects and therefore could not be approved under §404 or §405
respectively. Furthermore, it concluded that "these [non-obese healthy children] do not have a
disease or condition," many of the interventions and procedures were not reasonably
commensurate with those inherent in their actual or expected situations, and the risks exceeded a
minor increase over minimal risk, therefore the study could not be approved under §406 either.
The OFIRP recommended that §407 approval be sought and later terminated the trial 77
The differences between the Amiel study and NICHD study seem slight, yet the
outcomes are quite dissimilar. Why do the siblings of diabetic children qualify as having a
"disease or condition" (and therefore obtain §406 review) but the non-obese children of obese
parents do not? The siblings of the diabetic patients have a higher risk of developing diabetes
than the general population, but the same could be argued for the non-obese children. Did the
Yale IRB or the OHRP look at empiric evidence to determine how "at-risk" these children were in
their determination of what qualifies as a "condition or disorder"? It seems unlikely given that it
is questionable whether such data exist. Neither the Yale IRB, nor the OHRP elucidated the
definition of "disease or condition" on which they relied, yet the difference in the outcomes

94 Levine, supra note 5, at 249.

95 See Department of Health and Human Services, Office for Human Research Protections, OHRP
Compliance Activities, Determination Letters, (November 3, 2000, January 17, 2001 and October 30, 2002)
[hereinafter Determination Letters] (text available at:
<http://ohrp.osophs.dhhs.gov/detrm_letrs/lindex.htm>).
96 The specific intervention that posed more than minimal risk was a “clamp” study that required an
overnight stay in the hospital with the insertion of two intravenous catheters so that insulin and sugar could
be infused while taking blood samples. The study would manipulate each child’s blood sugar between 80200 mg/dL and measure the child’s response. See Eliot Marshall, Enforcers Halt NIH Study Called Less
Risky than Outdoor Play, 290 SCIENCE 1281 (2000).
97 See Determination Letter supra note 95, (November 3, 2000).
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hinges on these words.'"* Once again, it is obvious that reasonable people can and do interpret the
federal regulations differently and create drastically different end results.

§407: Research Not Otherwise Approvable
Finally, the last category outlined in Subpart D involves research that would not be
approvable under any of the aforementioned categories. In such cases, if the IRB finds that the
research presents a "reasonable opportunity to further understanding, prevention, or alleviation
of a serious problem affecting the health or welfare of children," then the Secretary of the DHHS
may consult with a panel of experts, provide an opportunity for public review and comment, and
then possibly approve the research.^ The Secretary can find the protocol acceptable by either
finding that the research actually does satisfy the conditions of §§404, 405, or 406, of that the
research (1) presents a reasonable opportunity to further the understanding, prevention, or
alleviation of a serious problem affecting the health or welfare of children; (2) will be conducted
in accordance with sound ethical principles; and (3) adequate provisions are made for soliciting
the assent of children and the permission of their parents or guardians as set forth in § 46.408.
Although this category has been used to permit research with children infrequently, the OHRP
lists six protocols as currently under §407 review.1'"’
In 1989, Prentice et al. published a description of a case that could not be approved under
§§404, 405 and 406, and which also was not suitable for §407.101 The protocol was designed, in
part, to determine whether biosynthetic growth hormone could promote linear growth in
children suffering from Turner Syndrome.

The control arm of the study was to receive placebo

injections three times per week, plus routine blood and urine exams, and radiographs of the
hands and wrists every six months to measure bone age. The multiple injections each week and

98

Although one could argue that even if the non-obese children were said to have a “condition or disorder”
the interventions posed more than a minor increase over minimal risk and still would not meet the
requirements of §406.
99 45 CFR §46.407.
100 See OHRP web site: <http://ohrp.osophs.dhhs.gov/cpanl.htm> (last visited Jan 30, 2004).
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the radiological examinations were judged to present more than minimal risk to the subjects, so
the protocol could not meet §404 approval. Furthermore, there was no firm evidence to support
the possibility that the placebo group would receive direct benefit from the injections under the
hypothesis that stress induces the release of natural growth hormone, so the protocol could not
satisfy §405. The protocol did not meet §406 approval because the fact that the placebo group
would miss the opportunity to be treated with available alternatives such as different types of
biosynthetic growth hormone, estrogens or androgens posed more than a minor increase over
minimal risk; the multiple injections over 18-months was not commensurate with the actual or
expected medical treatment of a patient with Turner syndrome; and the research would not yield
generalizable knowledge about Turner that is of vital importance for developing methods of
treatment because there was no evidence to show that the drug being tested would be any better
than another biosynthetic drug already being studied for the same purpose.

Finally, the IRB

decided that the protocol did not even qualify for §407 review because they did not think short
stature was a "serious" enough condition to warrant attempting to get §407 approval.1112
Interestingly, several years later, similar studies involving the use of growth hormone in children
with Turner syndrome or idiopathic short stature were presented to an expert panel for §407
review.1111 The studies were designed as a double-blind randomized control with half the children
receiving hGH and the other half receiving placebo injections three times a week for four to seven
years. Although the nine-member panel disagreed about the risks involved with the study, in the
end, there was only one member of the panel who thought the study could not be justified."’ The
differences in the study described by Prentice and these more recent studies seem slight, yet the
latter was permitted under §407 review and the earlier one was not even able to receive §407
review. There may have been evolving thought over what constitutes a "serious" problem, but

101 See Ernest D. Prentice et a!., Can Children be Enrolled in a Placebo-Controlled Randomized Clinical
Trial of Synthetic Growth Hormone? IRB: ETHICS & HUMAN RESEARCH, 6-10 (Jan-Feb 1989).
102 Id. at 9.
10'1 See Kopelman supra note 64, at 755. Importantly, hGH was already the standard of care for Turner
Syndrome,
104 Id. Kopelman served as one of the co-chairs of the review panel and was the only dissenting member.
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the evidence once again points to the fact that reasonable people serving on different IRBs, facing
similar protocols, can reach very different results.1""
An example of a study recently approved under §407 was a protocol entitled: Precursors
to Diabetes in Japanese American Youth.1"" The study was to enroll 300 children of Japanese
ancestry and 150 Caucasian children to undergo several routine examinations plus blood draw
by venipuncture, intravenous glucose tolerance test, measurement of body composition by DEXA
and intra-abdominal fat determination by MRI. None of the interventions had the prospect of
direct benefit to the children, and several of these interventions were thought to involve more
than minimal risk. Nevertheless, the majority of the reviewing experts found that the study
could be approved under §407 pending that the protocol and consent forms be modified to
further reduce the risks to the subjects. The experts found that the study could be approved
because it presented a reasonable opportunity to understand, prevent, or alleviate a serious
problem affecting the health and welfare of children."
Some argue that this last category of research should be proscribed altogether. Lainie
Friedman Ross, asserts that research in this category is entirely immoral and that "the decision to
balance the well-being of a particular child against the possibility of significant societal benefit is
a utilitarian calculus which fails to respect the developing personhood of the individual child."108
Ross, however, is too quick to equate a utilitarian analysis with evil when, in fact, most research
ethics entails ethical justification according to a utilitarian analysis. It is equally possible to
imagine a child who wants to participate in a research trial that has no component which is
physically beneficial to him, but one where his psychological well-being is better off because his

ICb For an interesting discussion of whether a similar trial is ethically permissible involving children with
very short stature and not Turner Syndrome, see also Carol A. Tauer, The NIH Trials of Growth Hormone
for Short Stature, IRB: A REVIEW OF HUMAN SUBJECTS RESEARCH, 1-9 (May-June 1994).
106
J
Report on Expert Panel Review Under Subpart D of 45 CFR 46: Precursors to Diabetes in Japanese
American Youth, (text available at <http://ohrp.osophs.dhhs.gov/pdjay/expert.htm>) (August 13, 2001).
107 This reasoning implies that the NICHD study would have received §407 approval as well. See supra
note 95 and accompanying text.
108 Lainie F. Ross, Children as Research Subjects: A Proposal to Revise the Current Federal Regulations
Using a Moral Framework, 8 STAN. L. & POL'Y Rev. 159 at 167 (1997).
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participation in a study may help alleviate a serious problem affecting children.11'1' To prevent
such a child from participating in a trial may just as easily fail to respect that child's developing
personhood. The onus is on the researcher to carefully assess whether the benefits to the child
outweigh the risks, but the lack of physical benefits should not preclude this analysis. For
example, a trial that involves multiple daily painful procedures for the healthy control group but
has the potential benefit of alleviating a severe illness for the children in the intervention arms
may be considered by a healthy child to be a worthwhile sacrifice to make for the benefit of
others. A utilitarian calculus can just as easily take this into account and conclude that §407
offers reasonable safeguards for the welfare of children in these studies.
By devising four categories of risk, the federal regulations sought to provide a level of
protection for children that is proportionate to the level of risk to which they are exposed.
Nevertheless, although the regulations seek to provide guidance to IRBs about the acceptability
of research protocols, the language used in the regulations including "minor increase,"
"reasonably commensurate," "disorder or condition," and "serious problem," are sufficiently
vague so as to create a battleground over how to define these terms. Even the relatively welldefined term of "minimal risk" lends itself to multiple interpretations. Although some of these
words reach consensus meanings eventually, not all have done so. The definitional ambiguities
leave an incredible amount of power in the hands of the IRBs.

How can we ensure IRBs will

apply consistent interpretations of the definitions and generate results that reflect the
commitment to the principles of respect for persons, beneficence and justice? How can courts be
better informed when facing cases involving children as research subjects so that they do not
commit the same mistakes the Grimes Court made and produce large discrepancies between IRB
decisions and court decisions? One possible mechanism for improvement is to restructure the
institutional review board system.

!09 This very argument has been used to permit children to donate kidneys to their siblings or undergo bone
marrow transplant.
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Part IV: Recommendations for Change
Disagreements over which interventions pose minimal risk or minor increase over
minimal risk exist among experts in the field and among members of IRBs. In 1981, empirical
work by Janofsky and Starfield found significant differences among pediatric experts about how
to assess the risks of a venous blood draw, arterial puncture and gastric and intestinal
intubation.* 11" They concluded that the variability in risk assessment by those surveyed suggested
that their judgments were based on an inadequate body of knowledge.111 In 1982, Goldman and
Katz published a controversial study of IRBs that concluded that there were significant
inconsistencies in the application of the federal regulations among many IRBs and that there were
inconsistencies in the application of ethical, methodological, and informed-consent standards
within individuals IRBs.112 The researchers gave three imperfect protocols to different IRBs to
determine whether the boards would identify the ethical, methodological and consent form flaws
and how they would address these defects. Goldman and Katz reported that IRBs neglected to
make the appropriate objections to the protocols and that there were internal inconsistencies that
indicated failures of the individual IRBs. Levine responded to the study by explaining why the
Goldman-Katz protocols may have received substandard review compared to most of the
protocols presented to the Yale IRB.111 He reported that the Goldman-Katz protocols did not
make proper use of the primary reviewer system upon which Yale's system relies. Furthermore,
the protocols did not go through a second review after initial revisions were recommended,
thereby eliminating the opportunity to identify additional problems with the protocols.
Additionally, Goldman and Katz did not recognize some of the ethical objections made by the

110 Jeffrey Janofsky & Barbara Starfield. Assessment of Risk in Research on Children, 98 J. OF PEDIATRICS,
No. 5, 842-846(1981).
111 See id. at 845.
112 See Jerry Goldman & Martin D. Katz, Inconsistency and Institutional Review Boards, 248 J. Am. Med.
Ass’n,

No. 2, 197(1982).

113 See Robert J. Levine, Inconsistency and IRBs: Flaws in the Goldman-Katz Study, IRB: A REVIEW OF
Human Subjects Research, 4-8 (Jan-Feb 1984).
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Yale IRB and report them correctly.114 Given Levine's critique, one could assume that similar
types of problems may have occurred with the other IRBs that Goldman and Katz investigated.
Although the Goldman and Katz study definitely had flaws, there is no denying that
different IRBs do not always come to the same conclusion about the acceptability of a study.1"
Furthermore, as the discussion of words such as minimal risk, minor increase over minimal risk
and disease or condition in Part III reflects, IRBs continue to interpret these concepts differently
because they are difficult concepts from the outset. Even though the federal regulations attempt
to divide research protocols into four categories of risk and require additional protections for
children as the risks increase, the regulations obviously have not created a simple framework that
will always consistently be applied among different IRBs and within any particular IRB. While
perfect consistency may be an unattainable goal, given the importance of protecting human
subjects equally, it is certainly a defensible goal.
The NHRPAC's Children's Working Group recognized several problems present with
the interpretation of the current regulations governing clinical research involving children. The
group, however, concluded that the regulations do not need revision, but rather require
clarification. The group is currently soliciting members of research institutions to submit
examples of research protocol that would be approved under §§404, 405 and 406.116 They plan to
make the report widely available to other advisory committees currently considering the issue of
protection for children in research.

Although the Working Group efforts should be applauded,

their report is unlikely to provide long-term solutions to the problems of variable interpretation
of words and inconsistent application of the regulations because it is difficult to anticipate the
ethical problems that future protocols will pose.

114 See id. See also Gregory J. Hayes et al., A Survey of University Institutional Review Boards:
Characteristics, Policies, and Procedures, IRB: A Review OF Human SUBJECTS RESEARCH (May-June
1995). Hayes points to several problems with IRBs including lack of membership diversity, inadequate
expertise, observer drift, lack of an evaluation process and groupthink.
115 See supra discussions of Amiel and NICHD studies at p.35 and human growth hormone studies at p. 37.
116 See The Social and Behavioral Sciences Working Group on Human Research Protections web site at:
<http://www.aera.net/humansubjects/Posting-Children.pdf>.
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The current system relies heavily on IRBs to perform efficiently and appropriately. IRBs
are required to review fundable federal grant proposals involving human subjects and all FDA
regulated research as well as most other research involving human subjects to the extent
specified in their institutions' Federal Wide Assusrances. Additionally, IRBs must determine
adequacy of consent forms and conduct at least annual review of ongoing studies. Some have
argued that the increasing number and complexity of multicentered randomized clinical trials
overtax IRBs.117 Others have argued that the real problem is that IRBs are weighed down with
tedious, low-yield, time-consuming tasks.118 Further criticism of the entire system is that the
dependence on IRBs yields inconsistence results.
Mashaw wrote that if an IRB is to "do its core job well, we must live with its inevitable
incompetence at other tasks. Moreover, we must also live with the rather vague regulatory
standards and with the continuing inability of the Federal funding agencies to know for sure
whether IRBs are functioning effectively."117 True, maybe the current scheme imposes too many
demands on the local IRBs, but instead of accepting the weaknesses in the system, perhaps a
different system is needed.
One way to establish clarification of the current regulations and create a system that will
encourage greater consistency while maintaining some flexibility is to change the review board
system. A restructured system that distributes duties within a regulatory hierarchy will help
solve the current problems and, perhaps more importantly, provide a long-term solution by
establishing a permanent process by which to address new issues as they arise. Although the
proposal that follows discusses only the federal regulations involving children, one might
imagine a system where all protocols involving human subjects are able to use the restructured
review board system.

117 See William J. Burman et al.. Breaking the Camel’s Back: Multicenter Clinical Trials and Local
Institutional Review Boards, 134 Ann. OF INTERNAL Med. No. 2 152, 155 (2001).
118 See Robert J. Levine, Institutional Review Boards: A Crisis in Confidence, 134 Ann. OF INTERNAL Med.
No. 2 161 (2001).
119 See Levine supra note 5, at 327, quoting from J.L. Mashaw, Thinking About Institutional Review
Boards. In: The Presidential Commission for the Study of Ethical Problems in Medicine and Biomedical
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A Proposal to Restructure the Review Board System:
A new review board system will preserve the local IRBs, create twelve Regional Review

Boards (RRBs) and one National Review Board (NRB). The system will use a hierarchical
structure that is similar to the federal court system. (See Figure 1.) The structure will include
local IRBs with their current membership, but their duties will be slightly different. The local
IRBs will continue to review protocols as required by §46.108 and §46.109, except that under
certain circumstances, they will have the discretion or the requirement of forwarding protocols to
their RRB. Although minimal risk protocols are generally easy to spot, those protocols that do
not clearly fall under §404 review can be forwarded, at the discretion of the local IRB, for regional
review. Furthermore, protocols that are reviewed under §405 or §406 and are contentious with
regard to what level of risk exists, must be forwarded to the RRB. Those that are contentious will
include protocols where there is definite disagreement between IRB members over how to
classify the risks of the interventions and procedures, and where no precedent exists for
approving or rejecting such a protocol. The precedent may exist from a protocol reviewed by
that same local IRB, the appropriate RRB or the NRB. These rules regarding what may be
submitted for regional review should appropriately limit the number of cases that are sent to the
RRB, but still allow a sufficient number to pass to the RRB so that it gains experience addressing
these more difficult cases.
Finally, protocols that are determined to fall under §407 review and previously required
the assembly of an expert panel, will now receive automatic NRB review. §407 will be amended
to reflect that instead of asking the Secretary to consult with a panel of experts, the IRB will ask
the Secretary to consult with the NRB to make a decision based on the remaining requirements of
§407. The NRB will function as the expert panel in these cases.

Research: Whistleblowing in Biomedical Research: Policies and Procedures for Responding to Reports of
Misconduct, p. 3-22. U.S. Gov. Printing Office, Stock No. 040-000-00458-1, Washington, DC 1982.
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Figure 1: Analogous Structure of Federal Courts and Proposed Review Boards

The intention behind enabling local IRBs to forward protocols to the RRBs is to 1) remove
the responsibility of defining ambiguous terms from the IRBs who have minimal time to devote
to any one protocol; 2) encourage greater consistency between local IRBs in how they apply the
federal regulations by mandating that they look to precedents (including precedents from the
regional and national levels) when making decisions; 3) reduce the likelihood of conflicts of
interest and or bias that can exist when local IRBs review their colleagues' proposals; and 4)
perhaps, decrease some of the time that local IRB members devote to reviewing difficult
protocols. Accusations have been made that local IRB members often do not fully understand the
nuances between the words in the regulations and therefore, do not appropriately apply the
regulations.1'" This new regulatory structure removes the more sophisticated analyses from the
purview of local IRB members who, even if they have a genuine interest in research ethics, may
not have the time or desire for appropriate training or education in the field, and places them in
the hands of a more qualified body.

I“° See Bette-Jane Crigger, What Does it Mean to “Review" a Protocol? Johns Hopkins & OHRP, IRB: A

Review of Human Subjects Research, 13-15 (July-Aug 2001). During the OHRP investigation of the
IRB system at Johns Hopkins University, the OHRP concluded that Hopkins failed to protect human
subjects appropriately after the death of a healthy 24-year-old woman in research designed to study asthma
physiology. OHRP concluded that the large volume of research overburdened IRB members and chairs
and that members did not sufficiently understand the federal regulations.

46

In addition, investigators whose applications are denied at the local level will be
permitted to appeal their protocols to the RRB for reconsideration. Because the RRB will meet
less frequently than the local IRB and there will likely be a delay before a decision is made, most
investigators will be dissuaded from appealing their protocol unless they truly think it deserves
another review. Given the current lack of the need for an appeals process at some institutions, it
seems unlikely that this appellate function of the RRBs will be used very often, but it is still
valuable for it to exist.121 Finally, the local IRBs should continue to work closely with local
investigators, remain familiar with the local institutions, and educate themselves and others
regarding research ethics. The local IRBs unmatched experience with reviewing a large volume of
protocols will enable them to identify ambiguities in the regulations and problems with their
application best and send protocols exemplifying these problems to the RRB level.
The RRBs will be organized and tailored to fit their charge. There will be 12 regional
RRBs, each one serving a specific geographical jurisdiction, analogous to the federal Circuit
Courts, and they should meet at least once a month. Membership of an RRB should consist of
representatives from its local IRB constituents, but given the large number of local IRBs, a
revolving membership is needed to ensure adequate representation but manageable meetings
and discussions. Each IRB may nominate one member to serve on the RRB. The RRB Chair will
review all those nominated and assemble a board of 20-30 members that best reflect the
constituents and meets the requirements of §46.107. Furthermore, no more than one member
from any local IRB may serve on the RRB. Membership should not exceed three years, and a
revolving membership should create a system that allows different local IRBs have a turn serving
on the RRB. Large academic institutions with large numbers of research studies under review,
however, may end up serving on their RRB continually, but a different representative from the
institution should serve as the RRB member.

121

See Levine, supra note 5, at 341, for a report that an appeals process at Yale ceased to exist because
there were no requests for an appeal for over 15 years.
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In addition, there should be at least one member of the RRB with full-time duties. This
member will be responsible for writing a synopsis of the discussion and conclusion reached for
the cases presented. The intention is that this will include a more detailed summary than just
minutes of the meeting. It will be a sufficiently detailed synopsis that can serve as a precedent to
which local IRBs can turn for future guidance on similar issues. These case summaries should be
published and catalogued in a searchable database for easy access by IRBs, the NRB and
members of the public.
The RRB members will assume a higher degree of responsibility in understanding the
federal regulations and research ethics. To that end, members will be required to undergo a wellstructured, high-quality educational course. This is not to say that the local IRB members are
absolved of the duty to be well-informed of the federal regulations and research ethics, but rather
that a high-quality, time-consuming educational system will be easier to initiate with a smaller
number of self-selected individuals who have a veritable interest in research ethics.122

Perhaps,

such an education system could later be extended to local IRB members.
The charge to the RRBs will be to not only review the protocols sent by the local IRBs, but
to clearly summarize the way in which they choose to define certain terms in the regulations. In
other words, if the RRB decides that the child of obese parents qualifies as having a "condition"
the RRB must identify how they reached that conclusion. If they relied on specific data to make a
conclusion, that should be identified as well. Furthermore, they must be bound by their own
precedents and those set by the NRB. This will ensure that their decisions are internally
consistent and ideally, promote consistency between the various IRBs within their jurisdiction.
Because the members of the RRB will have a greater understanding of research ethics and the
regulatory guidelines due to their education on the subjects, they will be in a better position to
review these more difficult protocols. Furthermore, because they will not oversee the expedited
review protocols or the minimal risk protocols, they should, ideally, have more time to dedicate

122

Cf Levine, supra note 118, at 162. Levine calls for an education system for all IRB staff and members.
He further reflects on adding an accreditation system for IRBs and a certification system for IRB staff.

.
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to each of the protocols that comes before them for review. Finally, when the RRB members are
unable to reach a consensus decision on a particular protocol they will be permitted to send up to
20% of their protocols to the NRB.
Structurally, the benefit of having the RRBs follow the geographical boundaries of the
federal circuit courts is that if there are legal suits filed against the investigators in any of these
RRB-approved cases later, the district and circuit courts will be able to look at the RRB approval
summary statement to gain a better understanding as to why the protocol was approved. (See
Table 5). Undoubtedly, the RRB opinion will not be binding on the court, but it can serve as
expert opinion and evidence as to what happened in the protocol review process. For example,
under this new review board system the recruitment of children who were "at-risk" of lead
poisoning to live in partially lead-abated houses in the KKI protocol would have flagged the case
to go to RRB review because it would be debatable whether these children had a "condition or
disorder."

If the RRB granted approval, later the Grimes Court could have used the RRB written

report to help understand why the protocol was approved. One of the goals of creating a
regional review system is that it may prevent the development of a discrepancy between the
courts' legally binding opinions and the institutional review board decisions. By providing the
court system with a comprehensible, detailed summary of the discussion that occurred during
review, the court will be better able to understand the issues at bar and hopefully will be less
likely to overstep its bounds without regard to the consequences as did the Grimes court.

.
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Table 5: Circuit Court Jurisdiction
Circuit Court123

Geographical Jurisdiction_

1st Circuit

Maine, Massachusetts, New Hampshire, Puerto Rico and Rhode Island

2nd Circuit

Connecticut, New York and Vermont

3rd Circuit

Delaware, New Jersey, Pennsylvania and Virgin Islands

4th Circuit

Maryland, North Carolina, South Carolina, Virginia and West Virginia

5th Circuit

Louisiana, Mississippi and Texas
Kentucky, Michigan, Ohio and Tennessee

6th Circuit
8th Circuit

Illinois, Indiana and Wisconsin
Arkansas, Iowa, Minnesota, Missouri, Nebraska, North Dakota and South

9lh Circuit

Dakota
Alaska, Arizona, California, Guam, Hawaii, Idaho, Montana, Nevada,

7'h Circuit

Oregon and Washington
10'h Circuit

Colorado, Kansas, New Mexico, Oklahoma, Utah and Wyoming

ll,h Circuit

Alabama, Florida and Georgia

12th Circuit

District of Columbia

Because members of the RRB will be drawn from several local IRBs and the proposals
before them will be from a wide geographical area, the chances for a conflict of interest between a
member of the RRB and a researcher asking for approval is significantly reduced. The RRB
members will not be placed in the position of having to reject the research of their colleagues
while at the same time fully aware that their own research needs IRB approval soon. A regional
review system creates distance between the researcher and the approval process that removes
local pressures and allows for a better non-biased application of the federal regulations.1:4
Furthermore, because members would be from different IRBs, they will be encouraged to share
information about the structure and effectiveness of their own IRB so that they may learn from
one another.
Criticism launched against local IRBs has included the inability to police itself
appropriately. By having a second review board look at contentious protocols, the chances that
the same biases or improper review processes will occur diminishes and respect for the local IRB

123 There is also a Federal Circuit which has nationwide jurisdiction to hear appeals in patent law cases and
cases decided by the Court of International Trade and the Court of Federal Claims.
124 The Grimes Court claimed that such pressures were present in the Hopkins’s IRB and contributed to the
protocol being miscast as having beneficial components for the control groups.
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system should improve.12' Local IRBs that have received bad press in recent years will be better
able to regain the trust of their local community if the local community knows that an additional
regional review may occur when the protocols involve procedures or interventions whose risks
are not easily classified.
The National Review Board will consist of one member of each RRB and should meet at
least four times a year. Additional members should include experts in different disciplines and
segments of society, as is required by §46.107, but total membership should not exceed 20.
Membership may be derived from large and small institutions, policymakers, ethicists, lawyers,
patients, and advocates for vulnerable populations. Members will serve a maximum of five years
in order to create an evolving board that keeps up with developing ethical understandings,
changes in law and advances in types of medical research. It will also prevent the members from
becoming complacent in their duties. All members will be required to undergo extensive
educational training on research ethics and the federal regulations similar to the RRB
requirements for membership. NRB members should also have a thorough understanding of the
OHRP, the history and reports of the various committees that have been formed to address
human research issues (the National Commission, NHRPAC Workgroup etc.) and why or why
not these committees have been successful in carrying out their charges.

The NRB should aspire

to be the most successful of any of these bodies and draw upon the experiences of these prior
committees.
The NRB's duties will be to review those protocols that the RRBs ask it to review, grant
appellate review when an investigator has been denied at the IRB and RRB level (exceedingly

125 Note that the local IRBs are not entirely bypassed by this new system. They remain the initial reviewers
and are able to decide when to send a protocol for RRB review. Cf. Robert J. Levine & Louis Lasagna,
Demystifying Central Review Boards: Current Options and Future Directions, IRB: A Review OF HUMAN
SUBJECTS Research, 1-8, (Nov-Dec 2000). In his discussion of Central Review Boards, Levine asserts
that academically oriented IRBs are unlikely to delegate the entirety of their responsibilities to an off-site
review board.
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rare),126 and most importantly, draft memoranda that will clarify the language in the federal
regulations.
In its case-review duties, the NRB will have access to the summary opinions from all
twelve of the RRBs, plus a member from each RRB present at the meetings, and will be in the best
position to apply consistent applications of the regulations. Because it will have a substantially
smaller case-load than the RRBs, it should have more than adequate time to spend on each case
that it is asked to review.

The NRB should strive to reach consensus opinions, but if this is not

possible, at least a 2/3 majority should be required before a protocol can be approved. This
condition admittedly will and should protect human subjects at the expense of limiting some
important research.

Similar to the RRB system, the NRB should write a clear summary opinion

as to how and why it reached its conclusion. The NRB Chair will appoint a member of the NRB
to write the opinion for a particular case, and members may write additional concurring or
dissenting opinions if they wish.
The NRB will also serve as the "expert panel" for §407 review. Because it will have
representation from all around the country and members who are experts in the field, there
should be no need to assemble a separate expert panel. Furthermore, the NRB will be
knowledgeable about national practices and will ensure that the opinion is not out of line with
current RRB and IRB decisions. Moreover, by requiring the NRB to address the most problematic
protocols that raise the most difficult ethical issues, the NRB will begin to understand where the
real sources of conflict lie and how to best address them. The remainder of §407 will be
unchanged and the opportunity to consult with additional experts and the opportunity for public
review and comment will still exist.
The most important function of the NRB will be to draft memoranda to clarify the
current federal regulations and make suggestions to Congress regarding amendments to the
regulations as needed. Through their case decisions, the NRB members will gain experience in

126 Given that appeals to the NRB are likely to be rare, there should be no need for a certiorari process
analogous to the U.S. Supreme Court.
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defining terms such as "minimal risk," "minor increase," "reasonably commensurate," and
"disorder or condition." Because they will have actual experience with cases that they have had
to decide whether or not to approve during their case-review duties, they will be in a much better
position to issue these memoranda than the NHRPAC Working Group, National Bioethics
Advisory Committee or any of the various other governmental bodies that have called for
explication of the regulations. Much like a court that hears cases, the NRB will be able to see the
practical effects of their decisions and therefore prevent interpretative mistakes that are made
when one deals only with the theoretical application of the regulations.
Case-based ethical reasoning rather than purely theoretical reasoning will be far superior
in balancing the advancement of medical research with the protection of the rights and welfare of
human subjects. The NRB actions will create nationwide impact, and therefore, if their decisions
are viewed as gravely wrong, researchers will demand changes in the federal regulations. The
NRB members can consult national experts and use their experience to suggest appropriate
revisions to Congress. (See Table 6.)
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Table 6: Membership and Duties of New Review Board System
Board

Membership

Local
Institutional
Review Board

As currently defined
by §46.107 (at least
five members,
diversity of
backgrounds, at least
one member with
expertise in a
scientific area and on
member with
expertise in a
nonscientific area,
one member not
affiliated with the
institution)

(IRBs)

Functions/Expertise
• review research as currently conducted under §46.108 and §46.109
except:
protocols that involve interventions or procedures that not clearly
minimal risk or less may be forwarded to the appropriate RRB
for review accompanied by a statement for why review is
requested
protocols falling under §405 and §406 that are contentious due to
reliance on ambiguous regulatory language and have no prior
precedent for approval must be forwarded to the appropriate
RRB for review
protocols seeking §407 review must be forwarded to the NRB for
review
• review protocols as currently conducted under §46.110 (expedited
review)
• maintain familiarity with local institution conditions and investigators
• continue to work closely with investigators to assure human subject
protection
• educate investigators, board members and community members
regarding research ethics
• where not otherwise stated, the current IRB functions will continue
Specific Advantages:
• experience with reviewing large number of protocols best enables them
to identify ambiguities in the regulations and problems with their
application and send protocols exemplifying these problems to the RRB
level

Regional
Review Boards
(RRBs)

• no more than one
member from each
local 1RB

• review all protocols forwarded by IRBs

• revolving
membership so that
each RRB has no
more than 30
members and over
years, local IRBs
have the opportunity
to have a
representative serve
as a member of their
RRB

20% of all protocols may be sent

• appellate function for investigators denied at local level
• send protocols for review to NRB at RRB’s discretion, but no more than
• draft case summaries after making a decision and circulate that decision
to the NRB and the local IRB who conducted the initial review
• maintain familiarity with local IRBs decisions
Specific Advantages:
• information sharing between members from different institutions at
regional meetings
• time available to discuss areas of regulations that are ambiguous such as
“minor increase” “disease or condition" “vital importance" etc. and make
decisions accordingly

• membership not to
exceed 3 years
National
Review Board
(NRB)

• 12 members (one
from each RRB)

• review all protocols forwarded by RRBs
• review all §407 protocols

• additional

• appellate function for investigators denied at regional level

members, not to
exceed 8, drawn from
areas not otherwise
represented by the
RRB representatives;
these may be

• draft memoranda to clarify federal regulations as needed

investigators,
lawyers, ethicists etc.
• membership not to
exceed 5 years

• maintain familiarity with state and federal court cases involving human
subjects research and research ethics
• recommend changes to Congress as needed
• maintain familiarity with research studies nationwide and RRB review
decisions
Specific Advantages:
• ability to spend time drafting memoranda to clarify federal regulations
drawing upon their knowledge of the entire review board system and their
experience as a reviewing body

•
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Indeed, one might argue that a hierarchical review board system will be unwieldy and
approval of research protocols will take too long, but that is all the more reason to design the
system to function efficiently. With appropriate parsing of duties between the local, regional and
national review boards, each group can function more efficiently and ideally, with a lesser
workload. A more centralized review organization encourages greater consistency, but
maintaining the local IRBs and including 12 RRBs still allows for flexibility within the system.
Local IRBs also reserve their autonomy as they are the ones that decide which protocols to send
to the RRB. It may be that local IRBs will not handle this responsibility appropriately or refuse to
send protocols to their RRB. Although it is beyond the scope of this paper, such malfunctioning
within the local IRBs possibly could be dealt with by the accreditation systems that are in place
and beginning to function.127 Above the local level, the regional review system and the
requirement of creating a database of written summary opinions is designed to produce
information sharing between IRBs and there is incredible value to knowing how other local IRBs
operate. It seems clear that the Yale system, which uses a primary reviewer process, is believed
to work well,12* but certainly it is not the only method being used.12M Local IRBs would benefit
from learning about each other's processes to help increase efficiency and awareness of difficult
protocol decisions that are made. A hierarchical IRB system creates the opportunity for each
review board level to foster and develop specific strengths that will ultimately afford greater
protections for human subjects in clinical research.

Conclusion
Unethical research involving children has occurred throughout history. Only in recent
years have federal regulations been enacted in the United States to help prevent further

127 For information on accreditation programs, see the Association for the Accreditation of Human
Research Protection Programs, Inc. at: <http://www.aahrpp.org>.
128 See Levine, supra note 5, 328-341, for in depth look at Yale’s IRB system.
129 See David A. Blake, An Executive Committee System for IRBs, IRB: A REVIEW OF HUMAN SUBJECTS
RESEARCH, 8-9 (Nov 1982), for comparison of primary review system with Johns Hopkins executive
committee system.
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violations of human rights. The federal regulations are routed in the principles of respects for
persons, beneficence and justice. They create a valuable risk-based assessment system for
evaluating research protocols, but the regulations are fraught with imprecise language that often
leads to their inconsistent application and incongruous results.

The KKI lead abatement study,

the Amiel and NICHD studies of children who were at risk for diabetes and obesity respectively,
and the human growth hormone studies are just a few examples of protocols that, however wellintended, received widely differing views of their acceptability, and ultimately had diverse
outcomes.

The definitions of "minor increase," "reasonably commensurate," and "disorder or

condition" continue to plague those who are charged with interpreting the regulations.
The ambiguities in the federal regulations make them inherently difficult to apply and
because IRBs are charged with their application but not their revision, the IRBs are often blamed
for inconsistent and ineffective applications. Amidst the confusion over how to interpret words
in the regulations, it is not surprising that despite their best efforts individual IRBs have been
criticized for inappropriately accepting or denying research protocols. Clarification of the
regulations protecting children are inevitably needed, but the substantive changes to the
regulations will not be realized without first making procedural changes. The IRBs cannot take
on the additional duties of interpreting and possibly revising the regulations when they provide
inadequate guidance.
A new review board system, modeled after the federal court system, will redistribute
some of these responsibilities and create boards that are better able to carry out their specific
mandates. Local IRBs will continue to oversee minimal risk research, but will not be solely
responsible for interpreting the more ambiguous definitions in the regulations. Regional review
boards, with members who are well educated on research ethics and federal regulations, will
assume some of these duties. Finally, a national review board, which has some case-review
duties, will be best able use case-based ethical reasoning and carry out the mandate of drafting
memoranda that clarify the federal regulations and recommending changes to Congress as
needed. An overhaul of the review board system seems like a rather drastic proposal, but it may
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serve as the best way to efficiently and effectively ensure the protection of human subjects,
including children, according to the principles of respect for persons, beneficence and justice.
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Appendix 1
Department of Health and Human Services,
45 Code of Federal Regulations 46, Subpart D

TITLE 45 - PUBLIC WELFARE
SUBTITLE A - DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER A - GENERAL ADMINISTRATION
PART 46 - PROTECTION OF HUMAN SUBJECTS
SUBPART D - ADDITIONAL PROTECTIONS FOR CHILDREN INVOLVED AS SUBJECTS
IN RESEARCH
§ 46.401 To what do these regulations apply?
(a) This subpart applies to all research involving children as subjects, conducted or supported by
the Department of Health and Human Services.
(1) This includes research conducted by Department employees, except that each head of an
Operating Division of the Department may adopt such nonsubstantive, procedural modifications
as may be appropriate from an administrative standpoint.
(2) It also includes research conducted or supported by the Department of Health and Human
Services outside the United States, but in appropriate circumstances, the Secretary may, under
paragraph (e) of § 46.101 of Subpart A, waive the applicability of some or all of the requirements
of these regulations for research of this type.
(b) Exemptions at § 46.101(b)(1) and (b)(3) through (b)(6) are applicable to this subpart. The
exemption at § 46.101(b)(2) regarding educational tests is also applicable to this subpart.
However, the exemption at § 46.101(b)(2) for research involving survey or interview procedures
or observations of public behavior does not apply to research covered by this subpart, except for
research involving observation of public behavior when the investigator(s) do not participate in
the activities being observed.
(c) The exceptions, additions, and provisions for waiver as they appear in paragraphs (c) through
(i) of § 46.101 of Subpart A are applicable to this subpart.

§ 46.402 Definitions.
The definitions in § 46.102 of Subpart A shall be applicable to this subpart as well. In addition, as
used in this subpart:
(a) Children are persons who have not attained the legal age for consent to treatments or
procedures involved in the research, under the applicable law of the jurisdiction in which the
research will be conducted.
(b) Assent means a child's affirmative agreement to participate in research. Mere failure to object
should not, absent affirmative agreement, be construed as assent.
(c) Permission means the agreement of parent(s) or guardian to the participation of their child or
ward in research.
(d) Parent means a child's biological or adoptive parent.
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(e) Guardian means an individual who is authorized under applicable State or local law to
consent on behalf of a child to general medical care.
§ 46.403 IRB duties.
In addition to other responsibilities assigned to IRBs under this part, each IRB shall review
research covered by this subpart and approve only research which satisfies the conditions of all
applicable sections of this subpart.
§ 46.404 Research not involving greater than minimal risk.
HHS will conduct or fund research in which the IRB finds that no greater than minimal risk to
children is presented, only if the IRB finds that adequate provisions are made for soliciting the
assent of the children and the permission of their parents or guardians, as set forth in § 46.408.
§ 46.405 Research involving greater than minimal risk but presenting the prospect of direct
benefit to the individual subjects.
HHS will conduct or fund research in which the IRB finds that more than minimal risk to
children is presented by an intervention or procedure that holds out the prospect of direct benefit
for the individual subject, or by a monitoring procedure that is likely to contribute to the subject's
well-being, only if the IRB finds that:
(a) The risk is justified by the anticipated benefi t to the subjects;
(b) The relation of the anticipated benefit to the risk is at least as favorable to the subjects as that
presented by available alternative approaches; and
(c) Adequate provisions are made for soliciting the assent of the children and permission of their
parents or guardians, as set forth in § 46.408.

§ 46.406 Research involving greater than minimal risk and no prospect of direct benefit to
individual subjects, but likely to yield generalizable knowledge about the subject's disorder or
condition.
HHS will conduct or fund research in which the IRB finds that more than minimal risk to
children is presented by an intervention or procedure that does not hold out the prospect of
direct benefit for the individual subject, or by a monitoring procedure which is not likely to
contribute to the well-being of the subject, only if the IRB finds that:
(a) The risk represents a minor increase over minimal risk;
(b) The intervention or procedure presents experiences to subjects that are reasonably
commensurate with those inherent in their actual or expected medical, dental, psychological,
social, or educational situations;
(c) The intervention or procedure is likely to yield generalizable knowledge about the subjects'
disorder or condition which is of vital importance for the understanding or amelioration of the
subjects’ disorder or condition; and

'
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(d) Adequate provisions are made for soliciting assent of the children and permission of their
parents or guardians, as set forth in § 46.408.

§ 46.407 Research not otherwise approvable which presents an opportunity to understand,
prevent, or alleviate a serious problem affecting the health or welfare of children.
HHS will conduct or fund research that the IRB does not believe meets the requirements of §
46.404, § 46.405, or § 46.406 only if:
(a) The IRB finds that the research presents a reasonable opportunity to further the
understanding, prevention, or alleviation of a serious problem affecting the health or welfare of
children; and
(b) The Secretary, after consultation with a panel of experts in pertinent disciplines (for example:
science, medicine, education, ethics, law) and following opportunity for public review and
comment, has determined either:
(1) That the research in fact satisfies the conditions of § 46.404, § 46.405, or § 46.406, as applicable,
or
(2) The following:
(i) The research presents a reasonable opportunity to further the understanding, prevention, or
alleviation of a serious problem affecting the health or welfare of children;
(ii) The research will be conducted in accordance with sound ethical principles;
(iii) Adequate provisions are made for soliciting the assent of children and the permission of their
parents or guardians, as set forth in § 46.408.
§ 46.408 Requirements for permission by parents or guardians and for assent by children.
(a) In addition to the determinations required under other applicable sections of this subpart, the
IRB shall determine that adequate provisions are made for soliciting the assent of the children,
when in the judgment of the IRB the children are capable of providing assent. In determining
whether children are capable of assenting, the IRB shall take into account the ages, maturity, and
psychological state of the children involved. This judgment may be made for all children to be
involved in research under a particular protocol, or for each child, as the IRB deems appropriate.
If the IRB determines that the capability of some or all of the children is so limited that they
cannot reasonably be consulted or that the intervention or procedure involved in the research
holds out a prospect of direct benefit that is important to the health or well-being of the children
and is available only in the context of the research, the assent of the children is not a necessary
condition for proceeding with the research. Even where the IRB determines that the subjects are
capable of assenting, the IRB may still waive the assent requirement under circumstances in
which consent may be waived in accord with § 46.116 of Subpart A.
(b) In addition to the determinations required under other applicable sections of this subpart, the
IRB shall determine, in accordance with and to the extent that consent is required by § 46.116 of
Subpart A, that adequate provisions are made for soliciting the permission of each child's parents
or guardian. Where parental permission is to be obtained, the IRB may find that the permission of
one parent is sufficient for research to be conducted under § 46.404 or § 46.405. Where research is
covered by §§ 46.406 and 46.407 and permission is to be obtained from parents, both parents
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must give their permission unless one parent is deceased, unknown, incompetent, or not
reasonably available, or when only one parent has legal responsibility for the care and custody of
the child.
(c) In addition to the provisions for waiver contained in § 46.116 of Subpart A, if the IRB
determines that a research protocol is designed for conditions or for a subject population for
which parental or guardian permission is not a reasonable requirement to protect the subjects (for
example, neglected or abused children), it may waive the consent requirements in Subpart A of
this part and paragraph (b) of this section, provided an appropriate mechanism for protecting the
children who will participate as subjects in the research is substituted, and provided further that
the waiver is not inconsistent with Federal, state or local law. The choice of an appropriate
mechanism would depend upon the nature and purpose of the activities described in the
protocol, the risk and anticipated benefit to the research subjects, and their age, maturity, status,
and condition.
(d) Permission by parents or guardians shall be documented in accordance with and to the extent
required by § 46.117 of Sub part A.
(e) When the IRB determines that assent is required, it shall also determine whether and how
assent must be documented.
§ 46.409 Wards.
(a) Children who are wards of the state or any other agency, institution, or entity can be included
iir research approved under § 46.406 or § 46.407 only if such research is:
(1) Related to their status as wards; or
(2) Conducted in schools, camps, hospitals, institutions, or similar settings in which the majority
of children involved as subjects are not wards.
(b) If the research is approved under paragraph (a) of this section, the IRB shall require
appointment of an advocate for each child who is a ward, in addition to any other individual
acting on behalf of the child as guardian or in loco parentis. One individual may serve as
advocate for more than one child. The advocate shall be an individual who has the background
and experience to act in, and agrees to act in, the best interests of the child for the duration of the
child's participation in the research and who is not associated in any way (except in the role as
advocate or member of the IRB) with the research, the investigator(s), or the guardian
organization.

•:
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Appendix 2
THE NUREMBERG CODE

Permissible Medical Experiments
The great weight of the evidence before us to effect that certain types of medical experiments on
human beings, when kept within reasonably well-defined bounds, conform to the ethics of the
medical profession generally. The protagonists of the practice of human experimentation justify
their views on the basis that such experiments yield results for the good of society that are
unprocurable by other methods or means of study. All agree, however, that certain basic
principles must be observed in order to satisfy moral, ethical and legal concepts:
1.

The voluntary consent of the human subject is absolutely essential.

This means that the person involved should have legal capacity to give consent; should
be so situated as to be able to exercise free power of choice, without the intervention of any
element of force, fraud, deceit, duress, over-reaching, or other ulterior form of constraint or
coercion; and should have sufficient knowledge and comprehension of the elements of the
subject matter involved as to enable him to make an understanding and enlightened decision.
This latter element requires that before the acceptance of an affirmative decision by the
experimental subject there should be made known to him the nature, duration, and purpose of
the experiment; the method and means by which it is to be conducted; all inconveniences and
hazards reasonably to be expected; and the effects upon his health or person which may possibly
come from his participation in the experiment.
The duty and responsibility for ascertaining the quality of the consent rests upon each
individual who initiates, directs or engages in the experiment. It is a personal duty and
responsibility which may not be delegated to another with impunity.
2.

The experiment should be such as to yield fruitful results for the good of society,

unprocurable by other methods or means of study, and not random and unnecessary in nature.
3. The experiment should be so designed and based on the results of animal experimentation
and a knowledge of the natural history of the disease or other problem under study that the
anticipated results will justify the performance of the experiment.
4. The experiment should be so conducted as to avoid all unnecessary physical and mental
suffering and injury.
5. No experiment should be conducted where there is an a priori reason to believe that death or
disabling injury will occur; except, perhaps, in those experiments where the experimental
physicians also serve as subjects.
6.

The degree of risk to be taken should never exceed that determined by the humanitarian

importance of the problem to be solved by the experiment.
7.

Proper preparations should be made and adequate facilities provided to protect the

experimental subject against even remote possibilities of injury, disability, or death.
8. The experiment should be conducted only by scientifically qualified persons. The highest
degree of skill and care should be required through all stages of the experiment of those who
conduct or engage in the experiment.
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9.

During the course of the experiment the human subject should be at liberty to bring the

experiment to an end if he has reached the physical or mental state where continuation of the
experiment seemed to him to be impossible.
10. During the course of the experiment the scientist in charge must be prepared to terminate the
experiment at any stage, if he has probably [sic] cause to believe, in the exercise of the good faith,
superior skill and careful judgment required of him that a continuation of the experiment is likely
to result in injury, disability, or death to the experimental subject.
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Appendix 3
WORLD MEDICAL ASSOCIATION
DECLARATION OF HELSINKI
Adopted by the 18th World Medical Assembly Helsinki, Finland, June 1964
and amended by the 29th World Medical Assembly Tokyo, Japan, October 1975
35th World Medical Assembly Venice, Italy, October 1983
and the 41st World Medical Assembly Hong Kong, September 1989
Introduction
It is the mission of the physician to safeguard the health of the people. His or her knowledge and
conscience are dedicated to the fulfillment of this mission.
The Declaration of Geneva of the World Medical Assembly binds the physician with the words,
"The health of my patient will be my first consideration," and the International Code of Medical
Ethics declares that, "A physician shall act only in the patient's interest when providing medical
care which might have the effect of weakening the physical and mental condition of the patient."
The purpose of biomedical research involving human subjects must be to improve diagnostic,
therapeutic and prophylactic procedures and the understanding of the aetiology and
pathogenesis of disease.
In current medical practice most diagnostic, therapeutic or prophylactic procedures involve
hazards. This applies especially to biomedical research.
Medical progress is based on research which ultimately must rest in part on experimentation
involving human subjects.
In the field of biomedical research a fundamental distinction must be recognized between
medical research in which the aim is essentially diagnostic or therapeutic for a patient, and
medical research, the essential object of which is purely scientific and without implying direct
diagnostic or therapeutic value to the person subjected to the research.
Special caution must be exercised in the conduct of research which may affect the environment,
and the welfare of animals used for research must be respected.
Because it is essential that the results of laboratory experiments be applied to human beings to
further scientific knowledge and to help suffering humanity, the World Medical Association has
prepared the following recommendations as a guide to every physician in biomedical research
involving human subjects. They should be kept under review in the future. It must be stressed
that the standards as drafted are only a guide to physicians all over the world. Physicians are not
relieved from criminal, civil and ethical responsibilities under the laws of their own countries.
I. Basic principles
1.

Biomedical research involving human subjects must conform to generally accepted

scientific principles and should be based on adequately performed laboratory and animal
experimentation and on a thorough knowledge of the scientific literature.
2.

The design and performance of each experimental procedure involving human subjects

should be clearly formulated in an experimental protocol which should be transmitted for
consideration, comment and guidance to a specially appointed committee independent of the
investigator and the sponsor provided that this independent committee is in conformity with the
laws and regulations of the country in which the research experiment is performed.
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3.

Biomedical research involving human subjects should be conducted only by scientifically

qualified persons and under the supervision of a clinically competent medical person. The
responsibility for the human subject must always rest with a medically qualified person and
never rest on the subject of the research, even though the subject has given his or her consent.
4.

Biomedical research involving human subjects cannot legitimately be carried out unless

the importance of the objective is in proportion to the inherent risk to the subject.
5.

Every biomedical research project involving human subjects should be preceded by

careful assessment of predictable risks in comparison with foreseeable benefits to the subject or to
others. Concern for the interests of the subject must always prevail over the interests of science
and society.
6.

The right of the research subject to safeguard his or her integrity must always be

respected. Every precaution should be taken to respect the privacy of the subject and to minimize
the impact of the study on the subject's physical and mental integrity and on the personality of
the subject.
7.

Physicians should abstain from engaging in research projects involving human subjects

unless they are satisfied that the hazards involved are believed to be predictable. Physicians
should cease any investigation if the hazards are found to outweigh the potential benefits.
8.

In publication of the results of his or her research, the physician is obliged to preserve the

accuracy of the results. Reports of experimentation not in accordance with the principles laid
down in this Declaration should not be accepted for publication.
9.

In any research on human beings, each potential subject must be adequately informed of

the aims, methods, anticipated benefits and potential hazards of the study and the discomfort it
may entail. He or she should be informed that he or she is a liberty to abstain from participation
in the study and that he or she is free to withdraw his or her consent to participation at any time.
The physician should then obtain the subject's freely-given informed consent, preferably in
writing.
10.

When obtaining informed consent for the research project the physician should be

particularly cautious if the subject is in a dependent relationship to him or her or may consent
under duress. In that case the informed consent should be obtained by a physician who is not
engaged in the investigation and who is completely independent of this official relationship,
11.

In case of legal incompetence, informed consent should be obtained from the legal

guardian in accordance with national legislation. Where physical or mental incapacity makes it
impossible to obtain informed consent, or when the subject is a minor, permission from the
responsible relative replaces that of the subject in accordance with national legislation.
Whenever the minor child is in fact able to give a consent, the minor's consent must be obtained
in addition to the consent of the minor's legal guardian.
12.

The research protocol should always contain a statement of the ethical considerations

involved and should indicate that the principles enunciated in the present Declaration are
complied with.
II. Medical research combined with clinical care (Clinical research)
1.

In the treatment of the sick person, the physician must be free to use a new diagnostic

and therapeutic measure, if in his or her judgment it offers hope of saving life, reestablishing
health or alleviating suffering.
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2.

The potential benefits, hazards and discomfort of a new method should be weighed

against the advantages of the best current diagnostic and therapeutic methods.
3.

In any medical study, every patient - including those of a control group, if any—should be

assured of the best proven diagnostic and therapeutic method.
4.

The refusal of the patient to participate in a study must never interfere with the

physician-patient relationship.
5.

If the physician considers it essential not to obtain informed consent, the specific reasons

for this proposal should be stated in the experimental protocol for transmission to the
independent committee (I, 2).
6.

The physician can combine medical research with professional care, the objective being

the acquisition of new medical knowledge, only to the extent that medical research is justified by
its potential diagnostic or therapeutic value for the patient.
III. Non-therapeutic biomedical research involving human subjects (Non-clinical biomedical

research)
1.

In the purely scientific application of medical research carried out on a human being, it is

the duty of the physician to remain the protector of the life and health of that person on whom
biomedical research is being carried out.
2.
The subjects should be volunteers—either healthy persons or patients for whom the
experimental design is not related to the patient's illness.
3.

The investigator or the investigating team should discontinue the research if in his/her

or their judgment it may, if continued, be harmful to the individual.
4.
In research on man, the interest of science and society should never take precedence over
considerations related to the well being of the subject.
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Appendix 4
Department of Health and Human Services,
45 Code of Federal Regulations 46,
Selected Sections Relating to Institutional Review Boards

TITLE 45 - PUBLIC WELFARE
SUBTITLE A - DEPARTMENT OF HEALTH AND HUMAN SERVICES
SUBCHAPTER A - GENERAL ADMINISTRATION
PART 46 - PROTECTION OF HUMAN SUBJECTS
SUBPART A - BASIC HHS POLICY FOR PROTECTION OF HUMAN RESEARCH SUBJECTS

§ 46.103 Assuring compliance with this policy—research conducted or supported by any Federal
Department or Agency.
(a) Each institution engaged in research which is covered by this policy and which is conducted
or supported by a federal department or agency shall provide written assurance satisfactory to
the department or agency7 head that it will comply with the requirements set forth in this policy.
In lieu of requiring submission of an assurance, individual department or agency heads shall
accept the existence of a current assurance, appropriate for the research in question, on file with
the Office for Protection from Research Risks, HHS, and approved for federalwide use by that
office. When the existence of an HHS-approved assurance is accepted in lieu of requiring
submission of an assurance, reports (except certification) required by this policy to be made to
department and agency heads shall also be made to the Office for Protection from Research Risks,
HHS.
(b) Departments and agencies will conduct or support research covered by this policy only if the
institution has an assurance approved as provided in this section, and only if the institution has
certified to the department or agency head that the research has been reviewed and approved by
an IRB provided for in the assurance, and will be subject to continuing review by the IRB.
Assurances applicable to federally supported or conducted research shall at a minimum include:
(1) A statement of principles governing the institution in the discharge of its responsibilities for
protecting the rights and welfare of human subjects of research conducted at or sponsored by the
institution, regardless of whether the research is subject to federal regulation. This may include
an appropriate existing code, declaration, or statement of ethical principles, or a statement
formulated by the institution itself. This requirement does not preempt provisions of this policy
applicable to department- or agency-supported or regulated research and need not be applicable
to any research exempted or waived under § 46.101 (b) or (i).
(2) Designation of one or more IRBs established in accordance with the requirements of this
policy, and for which provisions are made for meeting space and sufficient staff to support the
IRB's review and recordkeeping duties.
(3) A list of IRB members identified by name; earned degrees; representative capacity7; indications
of experience such as board certifications, licenses, etc., sufficient to describe each member's chief
anticipated contributions to IRB deliberations; and any employment or other relationship
between each member and the institution; for example: full-time employee, part-time employee,
member of governing panel or board, stockholder, paid or unpaid consultant. Changes in IRB
membership shall be reported to the department or agency head, unless in accord with §
46.103(a) of this policy, the existence of an HHS-approved assurance is accepted. In this case.
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change in IRB membership shall be reported to the Office for Protection from Research Risks,
HHS.
(4) Written procedures which the IRB will follow (i) for conducting its initial and continuing
review of research and for reporting its findings and actions to the investigator and the
institution; (ii) for determining which projects require review more often than annually and
which projects need verification from sources other than the investigators that no material
changes have occurred since previous IRB review; and (iii) for ensuring prompt reporting to the
IRB of proposed changes in a research activity, and for ensuring that such changes in approved
research, during the period for which IRB approval has already been given, may not be initiated
without IRB review and approval except when necessary to eliminate apparent immediate
hazards to the subject.
(5) Written procedures for ensuring prompt reporting to the IRB, appropriate institutional
officials, and the department or agency head of (i) any unanticipated problems involving risks to
subjects or others or any serious or continuing noncompliance with this policy or the
requirements or determinations of the IRB and (ii) any suspension or termination of IRB
approval.
(c) The assurance shall be executed by an individual authorized to act for the institution and to
assume on behalf of the institution the obligations imposed by this policy and shall be filed in
such form and manner as the department or agency head prescribes.
(d) The department or agency head will evaluate all assurances submitted in accordance with this
policy through such officers and employees of the department or agency and such experts or
consultants engaged for this purpose as the department or agency head determines to be
appropriate. The department or agency head's evaluation will take into consideration the
adequacy of the proposed IRB in light of the anticipated scope of the institution's research
activities and the types of subject populations likely to be involved, the appropriateness of the
proposed initial arid continuing review procedures in light of the probable risks, and the size and
complexity of the institution.
(e) On the basis of this evaluation, the department or agency head may approve or disapprove
the assurance, or enter into negotiations to develop an approvable one. The department or
agency head may limit the period during which any particular approved assurance or class of
approved assurances shall remain effective or otherwise condition or restrict approval.
(f) Certification is required w7hen the research is supported by a federal department or agency
and not otherwise exempted or waived under § 46.101 (b) or (i). An institution with an approved
assurance shall certify^ that each application or proposal for research covered by the assurance
and by § 46.103 of this Policy has been reviewed and approved by the IRB. Such certification
must be submitted with the application or proposal or by such later date as may be prescribed by
the department or agency to w7hich the application or proposal is submitted. Under no condition
shall research covered by § 46.103 of the Policy be supported prior to receipt of the certification
that the research has been reviewed and approved by the IRB. Institutions without an approved
assurance covering the research shall certify' within 30 days after receipt of a request for such a
certification from the department or agency, that the application or proposal has been approved
by7 the IRB. If the certification is not submitted within these time limits, the application or
proposal maybe returned to the institution.
§ 46.107 IRB membership.
(a) Each IRB shall have at least five members, with varying backgrounds to promote complete

.
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and adequate review of research activities commonly conducted by the institution. The IRB shall
be sufficiently qualified through the experience and expertise of its members, and the diversity of
the members, including consideration of race, gender, and cultural backgrounds and sensitivity
to such issues as community attitudes, to promote respect for its advice and counsel in
safeguarding the rights and welfare of human subjects. In addition to possessing the professional
competence necessary to review specific research activities, the IRB shall be able to ascertain the
acceptability of proposed research in terms of institutional commitments and regulations,
applicable law, and standards of professional conduct and practice. The IRB shall therefore
include persons knowledgeable in these areas. If an IRB regularly reviews research that involves
a vulnerable category of subjects, such as children, prisoners, pregnant women, or handicapped
or men tally disabled persons, consideration shall be given to the inclusion of one or more
individuals who are knowledgeable about and experienced in working with these subjects.
(b) Every nondiscriminatory effort will be made to ensure that no IRB consists entirely of men or
entirely of women, including the institution's consideration of qualified persons of both sexes, so
long as no selection is made to the IRB on the basis of gender. No IRB may consist entirely of
members of one profession.
(c) Each IRB shall include at least one member whose primary concerns are in scientific areas and
at least one member whose primary concerns are in nonscientific areas.
(d) Each IRB shall include at least one member who is not otherwise affiliated with the institution
and who is not part of the immediate family of a person who is affiliated with the institution.
(e) No IRB may have a member participate in the IRB's initial or continuing review of any project
in which the member has a conflicting interest, except to provide information requested by the
IRB.
(f) An IRB may, in its discretion, invite individuals with competence in special areas to assist in
the review of issues which require expertise beyond or in addition to that available on the IRB.
These individuals may not vote with the IRB.

§ 46.108 IRB functions and operations.
In order to fulfill the requirements of this policy each IRB shall:
(a) Follow written procedures in the same detail as described in § 46.103(b)(4) and, to the extent
required by, § 46.103(b)(5).
(b) Except when an expedited review procedure is used (see § 46.110), review proposed research
at convened meetings at which a majority of the members of the IRB are present, including at
least one member whose primary concerns are in nonscientific areas. In order for the research to
be approved, it shall receive the approval of a majority of those members present at the meeting.
§ 46.109 IRB Review of Research.
(a) An IRB shall review and have authority to approve, require modifications in (to secure
approval), or disapprove all research activities covered by this policy.
(b) An IRB shall require that information given to subjects as part of informed consent is in
accordance with § 46.116. The IRB may require that information, in addition to that specifically
mentioned in § 46.116, be given to the subjects when in the IRB's judgment the information
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would meaningfully add to the protection of the rights and welfare of subjects.
(c) An 1RB shall require documentation of informed consent or may waive documentation in
accordance with § 46.117.
(d) An IRB shall notify investigators and the institution in writing of its decision to approve or
disapprove the proposed research activity, or of modifications required to secure IRB approval of
the research activity. If the IRB decides to disapprove a research activity, it shall include in its
written notification a statement of the reasons for its decision and give the investigator an
opportunity to respond in person or in writing.
(e) An IRB shall conduct continuing review of research covered by this policy at intervals
appropriate to the degree of risk, but not less than once per year, and shall have authority to
observe or have a third party observe the consent process and the research.
§ 46.110 Expedited review procedures for certain kinds of research involving no more than
minimal risk, and for minor changes in approved research.
(a) The Secretary, HHS, has established, and published as a Notice in the FEDERAL REGISTER,
a list of categories of research that may be reviewed by the IRB through an expedited review
procedure. The list will be amended, as appropriate after consultation with other departments
and agencies, through periodic republication by the Secretary, HHS, in the FEDERAL REGISTER.
A copy of the list is available from the Office for Protection from Research Risks, National
Institutes of Health, HHS, Bethesda, Maryland 20892.
(b) An IRB may use the expedited review procedure to review either or both of the following:
(1) Some or all of the research appearing on the list and found by the reviewer(s) to involve no
more than minimal risk,
(2) Minor changes in previously approved research during the period (of one yrear or less) for
which approval is authorized.
Under an expedited review' procedure, the review may be carried out by the IRB chairperson or
by one or more experienced reviewers designated by the chairperson from among members of
the IRB. In reviewing the research, the reviewers may exercise all of the authorities of the IRB
except that the reviewers may not disapprove the research. A research activity may be
disapproved only after review in accordance with the non-expedited procedure set forth in §
46.108(b).
(c) Each IRB w'hich uses an expedited review procedure shall adopt a method for keeping all
members advised of research proposals which have been approved under the procedure.
(d) The department or agency head may restrict, suspend, terminate, or choose not to authorize
an institution's or IRB's use of the expedited review procedure.
§ 46.111 Criteria for IRB approval of research.
(a) In order to approve research covered by this policy the IRB shall determine that all of the
following requirements are satisfied:
(1) Risks to subjects are minimized: (i) By' using procedures w-hich are consistent with sound
research design and which do not unnecessarily expose subjects to risk, and (ii) whenever
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appropriate, by using procedures already being performed on the subjects for diagnostic or
treatment purposes.
(2) Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the
importance of the knowledge that may reasonably be expected to result. In evaluating risks and
benefits, the IRB should consider only those risks and benefits that may result from the research
(as distinguished from risks and benefits of therapies subjects would receive even if not
participating in the research). The IRB should not consider possible long-range effects of applying
knowledge gained in the research (for example, the possible effects of the research on public
policy) as among those research risks that fall within the purview' of its responsibility.
(3) Selection of subjects is equitable. In making this assessment the IRB should take into account
the purposes of the research and the setting in which the research will be conducted and should
be particularly cognizant of the special problems of research involving vulnerable populations,
such as children, prisoners, pregnant women, mentally disabled persons, or economically or
educationally disadvantaged persons.
(4) Informed consent will be sought from each prospective subject or the subject's legally
authorized representative, in accordance with, and to the extent required by § 46.116.
(5) Informed consent will be appropriately documented, in accordance wdth, and to the extent
required bv § 46.117.
(6) When appropriate, the research plan makes adequate provision for monitoring the data
collected to ensure the safety of subjects.
(7) When appropriate, there are adequate provisions to protect the privacy of subjects and to
maintain the confidentiality of data.
(b) When some or all of the subjects are likely to be vulnerable to coercion or undue influence,
such as children, prisoners, pregnant women, mentallv disabled persons, or economically or
educationally disadvantaged persons, additional safeguards have been included in the study to
protect the rights and welfare of these subjects.
§ 46.114 Cooperative research.
Cooperative research projects are those projects covered by this policy which involve more than
one institution. In the conduct of cooperative research projects, each institution is responsible for
safeguarding the rights and welfare of human subjects and for complying with this policy. With
the approval of the department or agency head, an institution participating in a cooperative
project may enter into a joint review arrangement, rely upon the review of another qualified IRB,
or make similar arrangements for avoiding duplication of effort.
§ 46.115 IRB records.
(a) An institution, or when appropriate an IRB, shall prepare and maintain adequate
documentation of IRB activities, including the following:
(1) Copies of all research proposals reviewed, scientific evaluations, if any, that accompany the
proposals, approved sample consent documents, progress reports submitted by investigators,
and reports of injuries to subjects.
(2) Minutes of IRB meetings which shall be in sufficient detail to show attendance at the
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meetings; actions taken by the IRB; the vote on these actions including the number of members
voting for, against, and abstaining; the basis for requiring changes in or disapproving research;
and a written summary of the discussion of controverted issues and their resolution.
(3) Records of continuing review activities.
(4) Copies of all correspondence between the IRB and the investigators.
(5) A list of IRB members in the same detail as described is § 46.103(b)(3).
(6) Written procedures for the IRB in the same detail as described in § 46.103(b)(4) and §
46.103(b)(5).
(7) Statements of significant new findings provided to subjects, as required by § 46.116(b)(5).
(b) The records required by this policy shall be retained for at least 3 years, and records relating
to research which is conducted shall be retained for at least 3 years after completion of the
research. All records shall be accessible for inspection and copying by authorized representatives
of the department or agency7 at reasonable times and in a reasonable manner.
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